A Phase 3 interventional study of Cabotegravir (CAB) tablet and Rilpivirine (RPV) tablet in HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 108 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 8th largest by enrollment, is one of 3 that started in 2016, is one of 12 in phase 3, reaches primary completion later than 1 of the 12 other live ones, and was the 11th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 631 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 15th largest by enrollment of the 210 interventional ones that give a count, is one of 8 that started in 2016, is one of 65 in phase 3, reaches primary completion later than 2 of the 26 other live ones, and was the 173rd registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-naïve adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) \<50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA \<50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.
Inclusion Criteria: - -1 infected, ART-naive men or women aged 18 years or greater at the time of signing the . - HIV-1 infection as documented by Screening plasma HIV-1 RNA >=1000 c/mL; - Antiretroviral-naive (\<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection). Any previous exposure to an HIV integrase inhibitor or non-nucleoside reverse transcriptase inhibitor will be exclusionary. - Female Participants: A female participant is eligible to participate if she is not pregnant at Screening and first day of Induction Phase (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: Non- defined as: Pre-menopausal females with one of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy; defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, and for at least 30 days after discontinuation of all oral study medications and for at least 52 weeks after discontinuation of CAB LA and RPV LA. The investigator is responsible for ensuring that participants understand how to properly use these methods of contraception. All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of HIV transmission to an uninfected partner. - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. - In France, a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
Exclusion Criteria: - Women who are pregnant, breastfeeding, or plan to become pregnant or breastfeed during the study. - Any evidence at Screening of an active Centers for Disease and Prevention Control (CDC) Stage 3 disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy or historic or current cluster of differentiation4+ (CD4+) cell count \<200 cells/ cubic millimeter (mm\^3) are not exclusionary. - Participants with known moderate to severe hepatic impairment. - Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant. - Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment. - Participant who, in the investigator's judgment, poses a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk. - The participant has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions. - Evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti HBc), Hepatitis B surface antibody (anti-HBs) and HBV dioxyribose nucleic acid (DNA) as follows: Participants positive for HBsAg are excluded; Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded. Note: Participants positive for anti-HBc (negative HBsAg status) and positive for anti-HBs (past and/or current evidence) are immune to HBV and are not excluded. - Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who are anticipated to require HCV treatment prior to Week 48 of the Maintenance Phase must be excluded. HCV treatment on study may be permitted post Week 48, following consultation with the Medical Monitor. Participants with HCV co-infection will be allowed entry into Phase 3 studies if: Liver enzymes meet entry criteria; HCV Disease has undergone appropriate work-up, HCV is not advanced, and will not require treatment prior to the Week 48 visit. Additional information (where available) on participants with HCV co-infection at screening should include results from any liver , fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment. In the event that recent biopsy or imaging data is not available or is inconclusive, the Fib-4 score will be used to verify eligibility. A Fib-4 score > 3.25 is exclusionary; Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 Score Formula: (Age x )/( x [square root of ALT]). - Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment). - History of liver cirrhosis with or without hepatitis viral co-infection. - Ongoing or pancreatitis. - All participants will be screened for syphilis (rapid plasma reagin [RPR]). Participants with untreated syphilis infection, defined as a positive RPR without clear documentation of treatment, are excluded. Participants with a positive RPR test who have not been treated may be rescreened at least 30 days after completion of antibiotic treatment for syphilis. - Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the study Medical Monitor for inclusion of the participant prior to enrollment. - Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug or render the participant unable to receive study medication. - History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during pharmacokinetic sampling (PK) sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled. - Current or anticipated need for chronic anti-coagulation. - Alanine aminotransferase (ALT) >=3 times upper limit normal (). - Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease. - Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of product (IP). - Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; tuberculosis (TB) therapy, with the exception of treatment of latent TB with isoniazid; Immunomodulators that alter immune responses (such as chronic systemic , interleukins, or interferons). Note: Participants using short-term (e.g. =\<21 day) systemic corticosteroid treatment, topical, inhaled or intranasal corticosteroids are eligible for enrollment. - Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening. - Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of the first dose of IP. - Use of medications which are associated with Torsades de Pointes - Any evidence of primary resistance to non-nuclease reverse transcriptase inhibitors (NNRTIs) (except for K103N which is allowed), or any known resistance to INIs from historical resistance test results. Note: re-tests of Screening genotypes are allowed only at the discretion of the study virologist. - Participants who are HLA-B*5701 positive and are unable to use an nuclease reverse transcriptase inhibitors (NRTI) backbone that does not contain abacavir (participants who are HLA-B*5701 positive may be enrolled if they use a NRTI backbone that does not contain abacavir; HLA-B*5701 positive participants may be excluded from the study if local provision of an alternate NRTI backbone is not possible). - Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening Phase to verify a result. - Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the participant's participation in the study of an investigational compound. - Participant has estimated \<50 mL/min/1.73m\^2 via the Chronic Kidney Disease Epidemiology Collaboration () equation. - Participants who are currently participating in or anticipate to be selected for any other interventional study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
Drug: Cabotegravir (CAB) tablet · Drug: Rilpivirine (RPV) tablet · Drug: Cabotegravir - Injectable Suspension (CAB LA) · Drug: Rilpivirine - Injectable Suspension (RPV LA)
After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
Drug: ABC/DTG/3TC STR - Tablet · Drug: DTG Tablet
It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose.
It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
It is a purple, biconvex, oval, tablet debossed with "572 Tri" on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with "SV 572" on one side and "50" on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.
Percentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48
Percentage of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the noninferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC regimen over 48 weeks in HIV-1 infected ARTexperienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks) or at time of discontinuation (if discontinuation occurred prior to Week 48 for reasons other than Adverse Event).
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48
Percentage of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks). Participants with no data in the analysis window were classificated as non-responders.
Time frame: Week 48
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48
Percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC
Time frame: Week 48
Number of Participants With Confirmed Virologic Failure (CVF) During the Maintenance Phase
The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL.
Time frame: Week 48
Absolute Values for Plasma HIV-1 RNA at Week 48
Plasma for quantitative HIV-1 RNA were collected at indicated time points. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.
Time frame: Week 48
Change From Baseline Values for Plasma HIV-1 RNA at Week 48
Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 minus HIV-1 RNA(log 10) at Baseline.
Time frame: Baseline (Day 1) and at Week 48
Absolute Values for CD4+ Lymphocyte Count at Week 48
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC
Time frame: Week 48
Change From Baseline Values for CD4+ Lymphocyte Count at Week 48
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value at Week 48 minus Maintenance Baseline value.
Time frame: Baseline (Day 1) and Week 48
Number of Participants With Disease Progression
Data for participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented. CDC stage is derived according to lowest post baseline CD4+ T-lympohocyte count and/or occurrence of AIDS-defining conditons (per 2014 CDC criteria).
Time frame: Day 1 up to an average of 59 weeks
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment. Safety Population: all randomized participants who received at least 1 dose of IP during maintenance phase and assessed according to actual treatment received. All Maintenance Phase AEs was presented including AEs with start date occurring on/after date of 1st dose of randomized treatment, up to and including start date of LTFU antiretroviral therapy for participants who discontinued from Q4W arm. Non-SAE counts in \>=5% of participants within any arm is reported
Time frame: Day 1 up to an average of 59 Weeks
Number of Participants With Severity of Adverse Events
Severity of adverse events (AEs) were defined as per The Division of acquired immuno deficiency syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE. All Maintenance Phase adverse events have been presented, which includes AEs with start date occuring on or after the date of first dose of randomized study treatment, up to and including the start date of LTFU antiretroviral therapy for participants who discontinued from the Q4W arm.
Time frame: Up to Week 48
Absolute Values for Hematology Parameters Over Time Including Week 48: Basophils, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocytes
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters Over Time Including Week 48: Hemoglobin
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters Over Time Including Week 48: Hematocrit
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated timepoints.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Fasting Lipid Panel Overtime Including Week 48
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.
Time frame: Baseline (Day 1) and at Week 48
Number of Participants With Abnormal Urinalysis Parameter Over Time Including Week 48
The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to DAIDS scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Erythrocytes
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Hematocrit
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Fasting Lipid Panel and Glucose Overtime Including Week 48
Blood samples were collected at Baseline and at Week 48 to assess glucose and fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Only fasting data is presented for glucose and lipids. Baseline value is defined as the last available fasting recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at Week 48 visit (if collected while fasting) minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine Creatinine Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine Phosphate Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine pH Over Time Including Week 48
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. All Maintenance Phase adverse events (start date occurring on or after the date of first dose of randomized study treatment) leading to withdrawal have been presented.
Time frame: Up to Week 48
Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the last available recorded fasting value up to and including the date of first Maintenance Phase dose of IP. Percentage change from baseline is calculated as: value at Week 48 (if collected while fasting) minus Baseline value divided by Baseline value multiplied by 100.
Time frame: Baseline (Day 1) and at Week 48
Number of Participants With Phenotypic Resistance Through Week 48
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Phenotypic Resistance data for following drugs :CAB,dolutegravir(DTG),elvitegravir (EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI),atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),ritonavir(RTV), saquinavir(SQV) and tipranavir (TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance (FC\>clinical higher cutoff/biologic cutoff),partially sensitive (FC=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC\<=clinical lower cutoff/biologic cutoff). The CVF population comprised of all participants in ITT-E population who met CVF criteria
Time frame: Week 48
Number of Participants With Genotypic Resistance Through Week 48
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
Time frame: Week 48
Area Under the Curve (AUC) for CAB LA
AUC values are Bayesian pharmacokinetic (PK) parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for CAB LA. The PK Population includes all participants who received CAB and / or RPV and undergo PK sampling during the study, and provide CAB and /or RPV plasma concentration data.
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48
AUC for RPV LA
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for RPV LA
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48
Plasma Trough Concentration (Ctrough) for CAB LA Evaluable
Blood samples were collected at indicated time points for PK analysis of CAB LA.
Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Ctrough for RPV LA Evaluable
Blood samples were collected at indicated time points for PK analysis of RPV LA.
Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41
Blood samples will be collected at indicated time points for PK analysis of CAB LA.
Time frame: Week 41- 1 Week post dose
Cmax in Plasma for RPV LA Evaluable at Week 41
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
Time frame: Week 41- 1 Week post dose
Change From Week 5 in Dimension Scores Using Perception of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF)
PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis
Time frame: Weeks 5 and at Weeks 41 and 48
Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire
PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment, following visit and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis.
Time frame: Weeks 5, 41 and 48
Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire
The HATQoL questionnaire was used to assess health related QoL (HRQoL). It comprises of three dimensions: life satisfaction (LISAT), medication worries (MEDWO) and disclosure worries (DISWO). For LISAT domain, each question is scored as 1-5, where 5 corresponds to satisfaction 'all of time' and 1 as 'none of time'. Total score for the LISAT domain (sum of item scores for questions 1a to 1d) is transformed to a 0-100 scale using formula:\[100 divided by (20 minus 4)\]\*(raw total score for LISAT minus 4). Higher the LISAT score, greater satisfaction to life. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 24 and 48
Change From Baseline in HIV Medication, MEDWO Using HATQoL
The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the MEDWO domain, each question is scored as 1-5, where 5 is associated with medication worry 'none of the time' and 1 as 'all of the time'. The total score for the MEDWO domain (sum of item scores for questions 2a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for MEDWO minus 5). Higher MEDWO scores correspond to lower medication worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Change From Baseline in DISWO Using HATQoL
The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the DISWO domain, each question is scored as 1-5, where 5 is associated with disclosure worry 'none of the time' and 1 as 'all of the time'. The total score for the DISWO domain (sum of item scores for questions 3a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for DISWO minus 5). Higher DISWO total scores correspond to lower disclosure worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)
The SF-12 questionnaire consists of 7 questions which measures degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. HRQoL using SF-12 for physical component summary (PCS) and mental component summary (MCS) were assessed for two treatment groups.Missing component scores was imputed using LOCF.PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com).The higher the score, the better will be the health status.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44
HIVTSQs (status version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value. Adjusted mean and 95% CI of adjusted mean values has been presented.
Time frame: Baseline and at Weeks 4b, 24 and 44
Change in Treatment Satisfaction Over Time Using HIVTSQc at Week 48
HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores representedeterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Time frame: Week 48
Change From Baseline in Individual Item Scores of HIVTSQs at Weeks 4b, 24 and 44
HIVTSQs (status version) is a 12 item questionnaire. The individual item scores are ratedas 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. LOCF was used as primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Weeks 4b, 24 and 44
Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire
ACCEPT questionnaire is generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication. It consists 25 items, capturing six dimensions. 3 questions focusing on general acceptance of study medication were analyzed. Items scores are rated as 1-5 :1-totally disagree,2-somewhat disagree,3-somewhat agree,4-totally agree and 5-I don't know. The acceptance domain score (ranging from 0 to 100) is calculated using the following formula:100\*(mean of recoded items in dimension minus 1) divided by 2.LOCF was primary method of analysis. Measure type is mean for adjusted mean and dispersion measure: 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Time frame: Baseline and at Weeks 8, 24 and 48
Change From 4b in Tolerability of Injection at Weeks 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm
The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.
Time frame: Weeks 4b, 5, 40 and 41
Number of Participants With Different Demographic Parameters for Inter-subject Variability
Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.
Time frame: Up to Week 48
This non-inferiority study evaluated antiviral activity of switching to intramuscular long acting carbotegravir (CAB) and rilpivirine (RPV) every 4 weeks compared to continuation of abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) over 48 weeks in virologically suppressed participants with human immunodeficiency type 1 infection
| Milestone | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Started | 283 | 283 |
| Completed | 0 | 0 |
| Not completed | 283 | 283 |
| Withdrew: On-going at the time of analysis | 258 | 261 |
| Withdrew: Physician decision | 2 | 5 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 7 | 7 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lack of efficacy | 5 | 3 |
| Withdrew: Adverse event | 9 | 4 |
Percentage of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the noninferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC regimen over 48 weeks in HIV-1 infected ARTexperienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks) or at time of discontinuation (if discontinuation occurred prior to Week 48 for reasons other than Adverse Event).
| Percentage of Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Percentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48 | 2.1 | 2.5 |
Percentage of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks). Participants with no data in the analysis window were classificated as non-responders.
| Percentage of Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48 | 94 | 93 |
Percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC
| Percentage of Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48 | 94 (91 to 97) | 94 (91 to 97) |
The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL.
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Number of Participants With Confirmed Virologic Failure (CVF) During the Maintenance Phase | 4 | 3 |
Plasma for quantitative HIV-1 RNA were collected at indicated time points. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.
| log10 copies/mL | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Absolute Values for Plasma HIV-1 RNA at Week 48 | 1.513 ± 0.0954 | 1.518 ± 0.1152 |
Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 minus HIV-1 RNA(log 10) at Baseline.
| log10 copies/mL | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Change From Baseline Values for Plasma HIV-1 RNA at Week 48 | -0.006 ± 0.1026 | 0.001 ± 0.1435 |
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC
| Cells per cubic millimeter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Absolute Values for CD4+ Lymphocyte Count at Week 48 | 703.2 ± 285.75 | 731.2 ± 272.49 |
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value at Week 48 minus Maintenance Baseline value.
| Cells per cubic millimeter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Change From Baseline Values for CD4+ Lymphocyte Count at Week 48 | 40.2 ± 195.17 | 79.9 ± 194.55 |
Data for participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented. CDC stage is derived according to lowest post baseline CD4+ T-lympohocyte count and/or occurrence of AIDS-defining conditons (per 2014 CDC criteria).
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Number of Participants With Disease Progression | 9 | 11 |
An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment. Safety Population: all randomized participants who received at least 1 dose of IP during maintenance phase and assessed according to actual treatment received. All Maintenance Phase AEs was presented including AEs with start date occurring on/after date of 1st dose of randomized treatment, up to and including start date of LTFU antiretroviral therapy for participants who discontinued from Q4W arm. Non-SAE counts in \>=5% of participants within any arm is reported
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Any non-SAE | 252 | 138 |
| Any SAE | 18 | 12 |
Severity of adverse events (AEs) were defined as per The Division of acquired immuno deficiency syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE. All Maintenance Phase adverse events have been presented, which includes AEs with start date occuring on or after the date of first dose of randomized study treatment, up to and including the start date of LTFU antiretroviral therapy for participants who discontinued from the Q4W arm.
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Grade 1 | 93 | 119 |
| Grade 2 | 143 | 95 |
| Grade 3 | 23 | 10 |
| Grade 4 | 8 | 1 |
| Grade 5 | 0 | 0 |
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.
| 10^9 cells per Liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Basophils, Baseline (Day 1), n=283, 283 | 0.022 ± 0.0124 | 0.022 ± 0.0138 |
| Basophils, Week 4, n=277, 270 | 0.024 ± 0.0136 | 0.024 ± 0.0142 |
| Basophils, Week 8, n=210, 272 | 0.023 ± 0.0135 | 0.023 ± 0.0122 |
| Basophils, Week 12, n=267, 272 | 0.025 ± 0.0166 | 0.023 ± 0.0144 |
| Basophils, Week 16, n=247, 259 | 0.030 ± 0.0212 | 0.028 ± 0.0209 |
| Basophils, Week 20, n=247, 259 | 0.035 ± 0.0254 | 0.032 ± 0.0256 |
| Basophils, Week 24, n=256, 260 | 0.037 ± 0.0245 | 0.036 ± 0.0256 |
| Basophils, Week 28, n=239, 258 | 0.039 ± 0.0249 | 0.038 ± 0.0247 |
| Basophils, Week 32, n=246, 263 | 0.044 ± 0.0254 | 0.038 ± 0.0246 |
| Basophils, Week 36, n=250, 259 | 0.042 ± 0.0237 | 0.040 ± 0.0250 |
| Basophils, Week 40, n=244, 245 | 0.041 ± 0.0248 | 0.041 ± 0.0252 |
| Basophils, Week 44, n=249, 260 | 0.040 ± 0.0246 | 0.040 ± 0.0257 |
| Basophils, Week 48, n=239, 258 | 0.038 ± 0.0214 | 0.038 ± 0.0246 |
| Eosinophils, Baseline (Day 1), n=283, 283 | 0.142 ± 0.1238 | 0.141 ± 0.1449 |
| Eosinophils, Week 4, n=277, 270 | 0.164 ± 0.1470 | 0.154 ± 0.1535 |
| Eosinophils, Week 8, n=210, 272 | 0.169 ± 0.1401 | 0.150 ± 0.1393 |
| Eosinophils, Week 12, n=267, 272 | 0.165 ± 0.1375 | 0.157 ± 0.1481 |
| Eosinophils, Week 16, n=247, 259 | 0.177 ± 0.1538 | 0.162 ± 0.1434 |
| Eosinophils, Week 20, n=247, 259 | 0.185 ± 0.1617 | 0.166 ± 0.1675 |
| Eosinophils, Week 24, n=256, 260 | 0.193 ± 0.1591 | 0.172 ± 0.1518 |
| Eosinophils, Week 28, n=239, 258 | 0.206 ± 0.1634 | 0.179 ± 0.1659 |
| Eosinophils, Week 32, n=246, 263 | 0.206 ± 0.1779 | 0.169 ± 0.1466 |
| Eosinophils, Week 36, n=250, 259 | 0.209 ± 0.2043 | 0.172 ± 0.1540 |
| Eosinophils, Week 40, n=244, 245 | 0.203 ± 0.1837 | 0.174 ± 0.1495 |
| Eosinophils, Week 44, n=249, 260 | 0.198 ± 0.1867 | 0.180 ± 0.1723 |
| Eosinophils, Week 48, n=239, 258 | 0.182 ± 0.1508 | 0.172 ± 0.1533 |
| Leukocytes, Baseline (Day 1), n=283, 283 | 5.82 ± 1.792 | 5.68 ± 1.684 |
| Leukocytes, Week 4, n=279, 272 | 6.41 ± 1.989 | 6.11 ± 1.770 |
| Leukocytes, Week 8, n=211, 275 | 6.04 ± 1.806 | 6.00 ± 1.714 |
| Leukocytes, Week 12, n=270, 275 | 5.88 ± 1.590 | 6.08 ± 1.836 |
| Leukocytes, Week 16, n=252, 265 | 6.08 ± 2.045 | 6.11 ± 1.887 |
| Leukocytes, Week 20, n=254, 265 | 6.08 ± 1.788 | 6.15 ± 1.926 |
| Leukocytes, Week 24, n=258, 264 | 6.11 ± 1.841 | 6.16 ± 2.046 |
| Leukocytes, Week 28, n=244, 263 | 6.17 ± 1.929 | 6.17 ± 1.939 |
| Leukocytes, Week 32, n=253, 266 | 6.07 ± 1.925 | 6.12 ± 1.918 |
| Leukocytes, Week 36, n=252, 259 | 6.11 ± 1.992 | 6.23 ± 2.104 |
| Leukocytes, Week 40, n=246, 253 | 5.96 ± 1.773 | 6.12 ± 2.076 |
| Leukocytes, Week 44, n=256, 262 | 6.03 ± 2.000 | 6.19 ± 1.970 |
| Leukocytes, Week 48, n=243, 260 | 5.85 ± 1.884 | 5.99 ± 1.986 |
| Lymphocytes, Baseline (Day 1), n=283, 283 | 2.022 ± 0.6893 | 1.957 ± 0.6408 |
| Lymphocytes, Week 4, n=277, 270 | 2.227 ± 0.7321 | 2.197 ± 0.7198 |
| Lymphocytes, Week 8, n=210, 272 | 2.102 ± 0.6980 | 2.110 ± 0.7015 |
| Lymphocytes, Week 12, n=267, 272 | 2.032 ± 0.6095 | 2.117 ± 0.7162 |
| Lymphocytes, Week 16, n=247, 259 | 2.028 ± 0.6931 | 2.130 ± 0.7245 |
| Lymphocytes, Week 20, n=247, 259 | 2.028 ± 0.6284 | 2.121 ± 0.6995 |
| Lymphocytes, Week 24, n=256, 260 | 2.014 ± 0.6456 | 2.111 ± 0.7092 |
| Lymphocytes, Week 28, n=239, 258 | 2.051 ± 0.6592 | 2.106 ± 0.6679 |
| Lymphocytes, Week 32, n=246, 263 | 2.037 ± 0.6543 | 2.112 ± 0.6950 |
| Lymphocytes, Week 36, n=250, 259 | 2.023 ± 0.6878 | 2.098 ± 0.6921 |
| Lymphocytes, Week 40, n=244, 245 | 2.021 ± 0.6646 | 2.030 ± 0.6357 |
| Lymphocytes, Week 44, n=249, 260 | 1.997 ± 0.6748 | 2.068 ± 0.6754 |
| Lymphocytes, Week 48, n=239, 258 | 1.926 ± 0.6126 | 2.003 ± 0.7651 |
| Monocytes, Baseline (Day 1), n=283, 283 | 0.382 ± 0.1666 | 0.366 ± 0.1705 |
| Monocytes, Week 4, n=277, 270 | 0.422 ± 0.1778 | 0.398 ± 0.1778 |
| Monocytes, Week 8, n=210, 272 | 0.415 ± 0.1824 | 0.380 ± 0.1771 |
| Monocytes, Week 12, n=267, 272 | 0.395 ± 0.1662 | 0.383 ± 0.1570 |
| Monocytes, Week 16, n=247, 259 | 0.438 ± 0.1859 | 0.409 ± 0.1810 |
| Monocytes, Week 20, n=247, 259 | 0.455 ± 0.1927 | 0.423 ± 0.1904 |
| Monocytes, Week 24, n=256, 260 | 0.438 ± 0.1859 | 0.438 ± 0.1897 |
| Monocytes, Week 28, n=239, 258 | 0.471 ± 0.1916 | 0.447 ± 0.2003 |
| Monocytes, Week 32, n=246, 263 | 0.462 ± 0.1898 | 0.459 ± 0.2107 |
| Monocytes, Week 36, n=250, 259 | 0.458 ± 0.2116 | 0.456 ± 0.2021 |
| Monocytes, Week 40, n=244, 245 | 0.438 ± 0.1740 | 0.442 ± 0.2038 |
| Monocytes, Week 44, n=249, 260 | 0.440 ± 0.1907 | 0.428 ± 0.1965 |
| Monocytes, Week 48, n=239, 258 | 0.402 ± 0.1911 | 0.396 ± 0.1857 |
| Neutrophils, Baseline (Day 1), n=283, 283 | 3.246 ± 1.3715 | 3.205 ± 1.2803 |
| Neutrophils, Week 4, n=277, 270 | 3.573 ± 1.5681 | 3.342 ± 1.3344 |
| Neutrophils, Week 8, n=210, 272 | 3.334 ± 1.3166 | 3.316 ± 1.3588 |
| Neutrophils, Week 12, n=267, 272 | 3.271 ± 1.2151 | 3.379 ± 1.4884 |
| Neutrophils, Week 16, n=247, 259 | 3.410 ± 1.7208 | 3.432 ± 1.5052 |
| Neutrophils, Week 20, n=247, 259 | 3.406 ± 1.4209 | 3.433 ± 1.5620 |
| Neutrophils, Week 24, n=256, 260 | 3.428 ± 1.4938 | 3.424 ± 1.6766 |
| Neutrophils, Week 28, n=239, 258 | 3.439 ± 1.5379 | 3.423 ± 1.5514 |
| Neutrophils, Week 32, n=246, 263 | 3.367 ± 1.5670 | 3.392 ± 1.4892 |
| Neutrophils, Week 36, n=250, 259 | 3.388 ± 1.5215 | 3.468 ± 1.6269 |
| Neutrophils, Week 40, n=244, 245 | 3.274 ± 1.3654 | 3.477 ± 1.7021 |
| Neutrophils, Week 44, n=249, 260 | 3.398 ± 1.5679 | 3.503 ± 1.5486 |
| Neutrophils, Week 48, n=239, 258 | 3.309 ± 1.4923 | 3.419 ± 1.5186 |
| Platelets, Baseline (Day 1), n=283, 282 | 226.7 ± 55.39 | 230.6 ± 58.33 |
| Platelets, Week 4, n=278, 269 | 233.1 ± 56.85 | 233.4 ± 56.56 |
| Platelets, Week 8, n=207, 273 | 226.9 ± 53.23 | 232.0 ± 56.31 |
| Platelets, Week 12, n=269, 271 | 226.6 ± 55.07 | 235.5 ± 57.26 |
| Platelets, Week 16, n=251, 263 | 225.5 ± 55.49 | 239.9 ± 70.40 |
| Platelets, Week 20, n=255, 264 | 233.8 ± 60.98 | 243.4 ± 62.06 |
| Platelets, Week 24, n=256, 261 | 233.9 ± 58.12 | 244.2 ± 59.95 |
| Platelets, Week 28, n=245, 258 | 233.7 ± 61.56 | 247.2 ± 63.18 |
| Platelets, Week 32, n=249, 262 | 235.0 ± 62.74 | 245.3 ± 60.25 |
| Platelets, Week 36, n=248, 259 | 237.3 ± 58.56 | 248.1 ± 59.57 |
| Platelets, Week 40, n=244, 254 | 233.9 ± 56.93 | 247.4 ± 63.85 |
| Platelets, Week 44, n=254, 261 | 236.7 ± 58.18 | 249.5 ± 71.56 |
| Platelets, Week 48, n=240, 255 | 232.8 ± 57.07 | 246.0 ± 70.35 |
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints.
| Femtoliters | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), n=283, 283 | 94.8 ± 4.94 | 94.3 ± 5.69 |
| Week 4, n=279, 273 | 94.1 ± 4.77 | 94.6 ± 5.85 |
| Week 8, n=211, 275 | 92.3 ± 4.86 | 94.6 ± 5.78 |
| Week 12, n=270, 275 | 91.0 ± 4.64 | 94.0 ± 5.81 |
| Week 16, n=254, 265 | 89.9 ± 4.43 | 94.1 ± 5.78 |
| Week 20, n=255, 267 | 89.3 ± 4.46 | 93.9 ± 5.64 |
| Week 24, n=259, 264 | 89.4 ± 4.33 | 93.8 ± 5.69 |
| Week 28, n=246, 265 | 89.3 ± 4.64 | 93.5 ± 5.78 |
| Week 32, n=254, 267 | 89.6 ± 4.69 | 93.6 ± 5.90 |
| Week 36, n=252, 261 | 89.5 ± 4.65 | 94.1 ± 5.65 |
| Week 40, n=246, 255 | 90.3 ± 4.62 | 94.4 ± 6.09 |
| Week 44, n=256, 262 | 90.7 ± 5.05 | 94.6 ± 6.32 |
| Week 48, n=243, 260 | 91.2 ± 5.21 | 95.4 ± 6.60 |
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints.
| 10^12 cells per Liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), n=283, 283 | 4.59 ± 0.434 | 4.65 ± 0.412 |
| Week 4, n=279, 273 | 4.67 ± 0.423 | 4.62 ± 0.406 |
| Week 8, n=211, 275 | 4.76 ± 0.435 | 4.67 ± 0.410 |
| Week 12, n=270, 275 | 4.82 ± 0.435 | 4.66 ± 0.419 |
| Week 16, n=254, 265 | 4.87 ± 0.430 | 4.66 ± 0.407 |
| Week 20, n=255, 267 | 4.89 ± 0.418 | 4.64 ± 0.410 |
| Week 24, n=259, 264 | 4.87 ± 0.418 | 4.67 ± 0.425 |
| Week 28, n=246, 265 | 4.87 ± 0.416 | 4.69 ± 0.395 |
| Week 32, n=254, 267 | 4.83 ± 0.435 | 4.66 ± 0.418 |
| Week 36, n=252, 261 | 4.82 ± 0.403 | 4.64 ± 0.395 |
| Week 40, n=246, 255 | 4.81 ± 0.407 | 4.63 ± 0.409 |
| Week 44, n=256, 262 | 4.79 ± 0.425 | 4.59 ± 0.403 |
| Week 48, n=243, 260 | 4.74 ± 0.443 | 4.59 ± 0.437 |
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints.
| Grams per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), n=283, 283 | 142.5 ± 13.59 | 143.1 ± 13.51 |
| Week 4, n=279, 273 | 144.3 ± 13.34 | 143.4 ± 13.47 |
| Week 8, n=211, 275 | 143.9 ± 13.84 | 144.7 ± 13.59 |
| Week 12, n=270, 275 | 144.5 ± 13.89 | 144.7 ± 14.66 |
| Week 16, n=254, 265 | 145.3 ± 13.52 | 144.6 ± 13.88 |
| Week 20, n=255, 267 | 145.4 ± 12.69 | 144.8 ± 13.87 |
| Week 24, n=259, 264 | 145.0 ± 13.14 | 145.3 ± 14.07 |
| Week 28, n=246, 265 | 145.3 ± 12.80 | 146.5 ± 14.17 |
| Week 32, n=254, 267 | 145.1 ± 13.37 | 146.2 ± 14.80 |
| Week 36, n=252, 261 | 144.6 ± 12.27 | 146.2 ± 13.85 |
| Week 40, n=246, 255 | 145.9 ± 12.32 | 146.2 ± 13.85 |
| Week 44, n=256, 262 | 145.1 ± 12.79 | 145.0 ± 14.13 |
| Week 48, n=243, 260 | 143.8 ± 13.56 | 145.4 ± 14.56 |
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints.
| Proportion of red blood cells in blood | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), n=283, 283 | 0.4341 ± 0.03889 | 0.4370 ± 0.03887 |
| Week 4, n=279, 273 | 0.4387 ± 0.03809 | 0.4363 ± 0.03832 |
| Week 8, n=211, 275 | 0.4382 ± 0.04056 | 0.4403 ± 0.03978 |
| Week 12, n=270, 275 | 0.4377 ± 0.04020 | 0.4373 ± 0.04144 |
| Week 16, n=254, 265 | 0.4366 ± 0.03769 | 0.4371 ± 0.03890 |
| Week 20, n=255, 267 | 0.4363 ± 0.03574 | 0.4349 ± 0.03839 |
| Week 24, n=259, 264 | 0.4351 ± 0.03580 | 0.4366 ± 0.03901 |
| Week 28, n=246, 265 | 0.4342 ± 0.03519 | 0.4374 ± 0.03867 |
| Week 32, n=254, 267 | 0.4318 ± 0.03623 | 0.4347 ± 0.04025 |
| Week 36, n=252, 261 | 0.4301 ± 0.03392 | 0.4349 ± 0.03774 |
| Week 40, n=246, 255 | 0.4328 ± 0.03433 | 0.4358 ± 0.03845 |
| Week 44, n=256, 262 | 0.4332 ± 0.03570 | 0.4328 ± 0.03847 |
| Week 48, n=243, 260 | 0.4310 ± 0.03875 | 0.4361 ± 0.04156 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated timepoints.
| International units per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| ALT, Baseline (Day 1), n=283, 283 | 28.7 ± 125.27 | 19.5 ± 14.76 |
| ALT, Week 4, n=281, 277 | 25.1 ± 64.74 | 17.9 ± 11.10 |
| ALT, Week 8, n=212, 278 | 20.8 ± 17.43 | 18.4 ± 11.34 |
| ALT, Week 12, n=270, 276 | 21.4 ± 16.94 | 19.2 ± 11.29 |
| ALT, Week 16, n=255, 269 | 21.6 ± 17.61 | 20.3 ± 13.34 |
| ALT, Week 20, n=260, 272 | 25.8 ± 72.51 | 19.6 ± 15.78 |
| ALT, Week 24, n=261, 268 | 23.9 ± 31.14 | 19.1 ± 11.91 |
| ALT, Week 28, n=253, 268 | 22.5 ± 19.78 | 19.6 ± 10.73 |
| ALT, Week 32, n=256, 268 | 38.5 ± 293.55 | 19.0 ± 11.56 |
| ALT, Week 36, n=255, 261 | 20.3 ± 13.92 | 21.2 ± 31.68 |
| ALT, Week 40, n=250, 266 | 20.9 ± 17.32 | 19.5 ± 12.35 |
| ALT, Week 44, n=258, 263 | 22.2 ± 27.14 | 19.8 ± 17.43 |
| ALT, Week 48, n=247, 262 | 20.1 ± 21.78 | 19.7 ± 16.58 |
| ALP, Baseline (Day 1), n=283, 283 | 66.5 ± 22.06 | 67.1 ± 22.98 |
| ALP, Week 4, n=281, 277 | 66.2 ± 19.56 | 65.5 ± 17.07 |
| ALP, Week 8, n=212, 278 | 66.8 ± 18.82 | 66.3 ± 17.49 |
| ALP, Week 12, n=270, 276 | 66.8 ± 19.80 | 66.1 ± 17.23 |
| ALP, Week 16, n=255, 269 | 66.7 ± 19.96 | 66.1 ± 17.89 |
| ALP, Week 20, n=260, 272 | 67.6 ± 19.11 | 65.6 ± 16.71 |
| ALP, Week 24, n=261, 268 | 67.1 ± 19.68 | 66.1 ± 17.96 |
| ALP, Week 28, n=253, 268 | 67.4 ± 20.05 | 67.5 ± 18.07 |
| ALP, Week 32, n=256, 268 | 68.0 ± 22.17 | 66.6 ± 17.65 |
| ALP, Week 36, n=255, 261 | 69.5 ± 26.86 | 68.3 ± 20.19 |
| ALP, Week 40, n=250, 266 | 67.4 ± 18.94 | 67.7 ± 18.30 |
| ALP, Week 44, n=258, 263 | 67.7 ± 18.59 | 68.2 ± 18.62 |
| ALP, Week 48, n=247, 262 | 66.4 ± 17.95 | 67.7 ± 18.15 |
| AST, Baseline (Day 1), n=283, 283 | 28.8 ± 90.66 | 22.5 ± 14.80 |
| AST, Week 4, n=281, 277 | 25.1 ± 32.67 | 20.9 ± 8.47 |
| AST, Week 8, n=212, 278 | 23.6 ± 20.85 | 20.5 ± 6.26 |
| AST, Week 12, n=270, 276 | 22.8 ± 10.38 | 21.0 ± 8.14 |
| AST, Week 16, n=255, 269 | 23.0 ± 10.71 | 22.8 ± 14.03 |
| AST, Week 20, n=260, 272 | 25.3 ± 32.64 | 22.7 ± 23.48 |
| AST, Week 24, n=261, 268 | 25.9 ± 25.16 | 21.2 ± 9.73 |
| AST, Week 28, n=253, 268 | 24.8 ± 16.50 | 21.7 ± 10.61 |
| AST, Week 32, n=256, 268 | 37.1 ± 233.23 | 20.7 ± 6.42 |
| AST, Week 36, n=255, 261 | 23.0 ± 12.44 | 22.4 ± 17.37 |
| AST, Week 40, n=250, 266 | 23.1 ± 12.22 | 21.0 ± 6.51 |
| AST, Week 44, n=258, 263 | 24.4 ± 15.66 | 21.9 ± 13.25 |
| AST Week 48, n=247, 262 | 22.3 ± 10.98 | 23.5 ± 42.49 |
| CK, Baseline (Day 1), n=283, 283 | 197.8 ± 291.21 | 199.8 ± 482.84 |
| CK, Week 4, n=280, 277 | 230.2 ± 447.94 | 173.0 ± 220.54 |
| CK, Week 8, n=212, 278 | 258.0 ± 928.82 | 152.9 ± 146.05 |
| CK, Week 12, n=270, 276 | 201.8 ± 348.13 | 182.6 ± 387.61 |
| CK, Week 16, n=255, 269 | 179.7 ± 248.71 | 234.0 ± 576.62 |
| CK, Week 20, n=260, 272 | 215.7 ± 539.34 | 258.9 ± 1109.04 |
| CK, Week 24, n=261, 268 | 248.6 ± 628.44 | 183.1 ± 368.02 |
| CK, Week 28, n=253, 268 | 252.7 ± 673.98 | 194.5 ± 506.24 |
| CK, Week 32, n=256, 268 | 175.8 ± 223.16 | 160.0 ± 176.09 |
| CK, Week 36, n=254, 261 | 219.0 ± 507.30 | 215.2 ± 460.38 |
| CK, Week 40, n=250, 266 | 220.5 ± 507.68 | 149.5 ± 115.14 |
| CK, Week 44, n=258, 263 | 254.0 ± 477.19 | 181.9 ± 428.28 |
| CK, Week 48, n=247, 262 | 185.5 ± 227.54 | 323.6 ± 2637.27 |
Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated timepoints.
| Grams per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), n=283, 283 | 43.8 ± 3.04 | 44.1 ± 2.80 |
| Week 4, n=280, 277 | 43.7 ± 3.03 | 43.8 ± 2.70 |
| Week 8, n=212, 278 | 43.5 ± 2.85 | 43.9 ± 2.76 |
| Week 12, n=270, 276 | 43.7 ± 3.06 | 44.1 ± 2.87 |
| Week 16, n=255, 269 | 44.1 ± 2.99 | 44.0 ± 2.78 |
| Week 20, n=260, 272 | 44.1 ± 3.11 | 43.9 ± 2.72 |
| Week 24, n=261, 268 | 44.3 ± 3.08 | 44.2 ± 2.60 |
| Week 28, n=253, 268 | 44.4 ± 3.09 | 44.5 ± 2.66 |
| Week 32, n=255, 268 | 44.6 ± 3.17 | 44.4 ± 2.76 |
| Week 36, n=254, 261 | 44.1 ± 3.05 | 44.3 ± 2.63 |
| Week 40, n=250, 266 | 44.8 ± 3.02 | 44.5 ± 2.76 |
| Week 44, n=258, 263 | 44.7 ± 2.98 | 44.4 ± 2.71 |
| Week 48, n=247, 262 | 44.6 ± 2.98 | 44.6 ± 2.86 |
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated timepoints.
| Micromoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Bilirubin, Baseline (Day 1), n=283, 283 | 9.3 ± 5.12 | 9.4 ± 4.68 |
| Bilirubin, Week 4, n=281, 277 | 10.7 ± 6.37 | 8.9 ± 4.40 |
| Bilirubin, Week 8, n=212, 278 | 10.1 ± 4.62 | 8.8 ± 3.85 |
| Bilirubin, Week 12, n=270, 276 | 10.5 ± 5.45 | 8.6 ± 3.53 |
| Bilirubin, Week 16, n=255, 269 | 10.6 ± 5.49 | 8.7 ± 3.74 |
| Bilirubin, Week 20, n=260, 272 | 10.3 ± 5.29 | 8.5 ± 3.40 |
| Bilirubin, Week 24, n=261, 268 | 10.0 ± 5.09 | 8.9 ± 3.86 |
| Bilirubin, Week 28, n=253, 268 | 10.4 ± 5.67 | 8.6 ± 3.90 |
| Bilirubin, Week 32, n=256, 268 | 10.5 ± 7.86 | 8.7 ± 3.95 |
| Bilirubin, Week 36, n=255, 260 | 9.9 ± 6.35 | 8.5 ± 3.42 |
| Bilirubin, Week 40, n=250, 266 | 10.2 ± 5.26 | 8.5 ± 3.52 |
| Bilirubin, Week 44, n=258, 263 | 10.3 ± 5.15 | 8.8 ± 3.78 |
| Bilirubin, Week 48, n=247, 262 | 10.3 ± 5.23 | 8.9 ± 3.71 |
| Direct bilirubin, Baseline (Day 1), n=283, 283 | 2.3 ± 1.32 | 2.2 ± 1.09 |
| Direct bilirubin, Week 4, n=277, 277 | 2.4 ± 1.47 | 2.1 ± 1.08 |
| Direct bilirubin, Week 8, n=212, 278 | 2.4 ± 1.17 | 2.1 ± 0.93 |
| Direct bilirubin, Week 12, n=269, 273 | 2.5 ± 1.26 | 2.1 ± 0.91 |
| Direct bilirubin, Week 16, n=254, 268 | 2.4 ± 1.46 | 2.1 ± 0.95 |
| Direct bilirubin, Week 20, n=260, 272 | 2.4 ± 1.54 | 2.1 ± 0.90 |
| Direct bilirubin, Week 24, n=260, 266 | 2.3 ± 1.20 | 2.1 ± 0.96 |
| Direct bilirubin, Week 28, n=253, 268 | 2.5 ± 1.29 | 2.1 ± 0.94 |
| Direct bilirubin, Week 32, n=256, 268 | 2.5 ± 3.48 | 2.1 ± 0.94 |
| Direct bilirubin, Week 36, n=255, 260 | 2.4 ± 2.24 | 2.0 ± 0.89 |
| Direct bilirubin, Week 40, n=249, 266 | 2.3 ± 1.29 | 2.1 ± 0.98 |
| Direct bilirubin, Week 44, n=258, 263 | 2.4 ± 1.34 | 2.1 ± 0.95 |
| Direct bilirubin, Week 48, n=247, 262 | 2.3 ± 1.26 | 2.2 ± 1.00 |
| Creatinine, Baseline (Day 1), n=283, 283 | 89.00 ± 16.061 | 85.80 ± 15.660 |
| Creatinine, Week 4, n=280, 277 | 82.99 ± 15.599 | 86.43 ± 14.655 |
| Creatinine, Week 8, n=212, 278 | 79.50 ± 14.103 | 85.50 ± 15.925 |
| Creatinine, Week 12, n=270, 276 | 79.25 ± 14.433 | 84.63 ± 15.155 |
| Creatinine, Week 16, n=255, 269 | 79.58 ± 14.509 | 85.18 ± 14.997 |
| Creatinine, Week 20, n=261, 272 | 78.50 ± 13.966 | 85.02 ± 15.488 |
| Creatinine, Week 24, n=262, 268 | 79.10 ± 15.340 | 85.05 ± 14.690 |
| Creatinine, Week 28, n=253, 268 | 78.79 ± 14.741 | 84.38 ± 15.023 |
| Creatinine, Week 32, n=255, 268 | 78.89 ± 14.558 | 84.50 ± 15.047 |
| Creatinine, Week 36, n=254, 262 | 79.58 ± 14.973 | 84.75 ± 14.352 |
| Creatinine, Week 40, n=250, 266 | 79.50 ± 15.615 | 84.70 ± 14.808 |
| Creatinine, Week 44, n=258, 263 | 80.04 ± 15.401 | 83.90 ± 14.604 |
| Creatinine, Week 48, n=247, 262 | 79.95 ± 15.613 | 90.88 ± 87.655 |
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated timepoints.
| Millimoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| CO2, Baseline (Day 1), n=283, 283 | 22.4 ± 2.24 | 22.4 ± 2.10 |
| CO2, Week 4, n=280, 276 | 23.0 ± 2.29 | 22.6 ± 2.28 |
| CO2, Week 8, n=212, 278 | 22.8 ± 2.07 | 22.3 ± 2.27 |
| CO2, Week 12, n=270, 276 | 22.6 ± 2.50 | 22.2 ± 2.34 |
| CO2, Week 16, n=255, 269 | 22.9 ± 2.40 | 22.3 ± 2.50 |
| CO2, Week 20, n=260, 272 | 22.8 ± 2.30 | 22.4 ± 2.32 |
| CO2, Week 24, n=261, 268 | 23.0 ± 2.71 | 22.8 ± 2.19 |
| CO2, Week 28, n=253, 268 | 23.0 ± 2.31 | 22.8 ± 2.47 |
| CO2, Week 32, n=255, 268 | 23.0 ± 2.31 | 22.7 ± 2.35 |
| CO2, Week 36, n=253, 261 | 23.1 ± 2.37 | 22.5 ± 2.26 |
| CO2, Week 40, n=249, 265 | 22.8 ± 2.34 | 22.6 ± 2.39 |
| CO2, Week 44, n=257, 263 | 22.9 ± 2.34 | 22.4 ± 2.12 |
| CO2, Week 48, n=247, 262 | 22.5 ± 2.18 | 22.3 ± 2.04 |
| Chloride, Baseline (Day 1), n=283, 283 | 104.6 ± 2.32 | 104.3 ± 2.32 |
| Chloride, Week 4, n=280, 277 | 104.6 ± 2.22 | 104.7 ± 2.13 |
| Chloride, Week 8, n=212, 278 | 104.7 ± 1.96 | 104.6 ± 2.32 |
| Chloride, Week 12, n=270, 276 | 104.6 ± 2.16 | 104.7 ± 2.35 |
| Chloride, Week 16, n=255, 269 | 104.4 ± 2.31 | 104.7 ± 2.24 |
| Chloride, Week 20, n=260, 272 | 104.3 ± 2.28 | 104.7 ± 2.06 |
| Chloride, Week 24, n=261, 268 | 104.4 ± 2.33 | 104.5 ± 2.42 |
| Chloride, Week 28, n=253, 268 | 104.5 ± 2.20 | 104.5 ± 2.28 |
| Chloride, Week 32, n=255, 268 | 104.4 ± 2.46 | 104.5 ± 2.33 |
| Chloride, Week 36, n=254, 261 | 104.4 ± 2.42 | 104.7 ± 2.20 |
| Chloride, Week 40, n=250, 266 | 104.8 ± 2.55 | 104.7 ± 2.25 |
| Chloride, Week 44, n=258, 263 | 104.7 ± 2.19 | 105.0 ± 2.22 |
| Chloride, Week 48, n=247, 262 | 104.7 ± 2.21 | 104.7 ± 2.28 |
| Glucose, Baseline (Day 1), n=283, 283 | 5.21 ± 1.632 | 5.17 ± 0.932 |
| Glucose, Week 4, n=236, 230 | 5.27 ± 1.322 | 5.23 ± 0.734 |
| Glucose, Week 8, n=172, 227 | 5.31 ± 1.347 | 5.19 ± 0.644 |
| Glucose, Week 12, n=229, 216 | 5.26 ± 0.911 | 5.27 ± 0.616 |
| Glucose, Week 16, n=204, 213 | 5.36 ± 1.804 | 5.28 ± 0.801 |
| Glucose, Week 20, n=209, 218 | 5.32 ± 0.735 | 5.26 ± 0.634 |
| Glucose, Week 24, n=221, 214 | 5.35 ± 1.219 | 5.21 ± 0.634 |
| Glucose, Week 28, n=207, 211 | 5.35 ± 1.633 | 5.23 ± 0.614 |
| Glucose, Week 32, n=201, 213 | 5.44 ± 1.355 | 5.27 ± 0.600 |
| Glucose, Week 36, n=199, 204 | 5.35 ± 0.797 | 5.31 ± 0.960 |
| Glucose, Week 40, n=203, 202 | 5.44 ± 1.319 | 5.35 ± 0.753 |
| Glucose, Week 44, n=208, 202 | 5.34 ± 0.991 | 5.35 ± 0.709 |
| Glucose, Week 48, n=248, 251 | 5.22 ± 0.895 | 5.22 ± 0.690 |
| Phosphate, Baseline (Day 1), n=283, 283 | 1.103 ± 0.1747 | 1.097 ± 0.1765 |
| Phosphate, Week 4, n=279, 277 | 1.137 ± 0.1774 | 1.112 ± 0.1850 |
| Phosphate, Week 8, n=212, 278 | 1.096 ± 0.1742 | 1.114 ± 0.1858 |
| Phosphate, Week 12, n=270, 276 | 1.097 ± 0.1802 | 1.106 ± 0.1876 |
| Phosphate, Week 16, n=255, 269 | 1.104 ± 0.1806 | 1.119 ± 0.1823 |
| Phosphate, Week 20, n=260, 272 | 1.078 ± 0.1843 | 1.114 ± 0.1812 |
| Phosphate, Week 24, n=261, 268 | 1.106 ± 0.1797 | 1.109 ± 0.1791 |
| Phosphate, Week 28, n=253, 268 | 1.094 ± 0.1814 | 1.119 ± 0.1893 |
| Phosphate, Week 32, n=255, 268 | 1.105 ± 0.1769 | 1.104 ± 0.1945 |
| Phosphate, Week 36, n=254, 261 | 1.102 ± 0.1862 | 1.122 ± 0.1872 |
| Phosphate, Week 40, n=250, 266 | 1.093 ± 0.1699 | 1.114 ± 0.1837 |
| Phosphate, Week 44, n=258, 263 | 1.096 ± 0.1851 | 1.120 ± 0.1903 |
| Phosphate, Week 48, n=247, 262 | 1.096 ± 0.1888 | 1.120 ± 0.2341 |
| Potassium, Baseline (Day 1), n=283, 283 | 4.12 ± 0.301 | 4.14 ± 0.288 |
| Potassium, Week 4, n=280, 277 | 4.27 ± 0.308 | 4.20 ± 0.327 |
| Potassium, Week 8, n=212, 278 | 4.22 ± 0.302 | 4.22 ± 0.343 |
| Potassium, Week 12, n=270, 276 | 4.21 ± 0.305 | 4.19 ± 0.282 |
| Potassium, Week 16, n=255, 269 | 4.21 ± 0.283 | 4.18 ± 0.303 |
| Potassium, Week 20, n=260, 272 | 4.21 ± 0.320 | 4.19 ± 0.313 |
| Potassium, Week 24, n=261, 268 | 4.24 ± 0.322 | 4.21 ± 0.312 |
| Potassium, Week 28, n=253, 268 | 4.20 ± 0.298 | 4.23 ± 0.294 |
| Potassium, Week 32, n=255, 268 | 4.21 ± 0.295 | 4.21 ± 0.315 |
| Potassium, Week 36, n=254, 261 | 4.21 ± 0.314 | 4.22 ± 0.314 |
| Potassium, Week 40, n=250, 266 | 4.19 ± 0.301 | 4.20 ± 0.305 |
| Potassium, Week 44, n=258, 263 | 4.21 ± 0.302 | 4.21 ± 0.324 |
| Potassium, Week 48, n=247, 262 | 4.13 ± 0.288 | 4.17 ± 0.449 |
| Sodium, Baseline (Day 1), n=283, 283 | 139.2 ± 1.89 | 139.2 ± 1.76 |
| Sodium, Week 4, n=280, 277 | 139.5 ± 1.98 | 139.4 ± 1.83 |
| Sodium, Week 8, n=212, 278 | 139.4 ± 1.78 | 139.3 ± 1.86 |
| Sodium, Week 12, n=270, 276 | 139.5 ± 1.80 | 139.3 ± 1.84 |
| Sodium, Week 16, n=255, 269 | 139.4 ± 1.76 | 139.4 ± 1.94 |
| Sodium, Week 20, n=260, 272 | 139.4 ± 1.75 | 139.5 ± 1.77 |
| Sodium, Week 24, n=261, 268 | 139.3 ± 1.82 | 139.4 ± 1.95 |
| Sodium, Week 28, n=253, 268 | 139.4 ± 1.80 | 139.5 ± 1.83 |
| Sodium, Week 32, n=255, 268 | 139.4 ± 1.83 | 139.4 ± 1.72 |
| Sodium, Week 36, n=254, 261 | 139.3 ± 1.87 | 139.5 ± 1.70 |
| Sodium, Week 40, n=250, 266 | 139.3 ± 2.04 | 139.5 ± 1.84 |
| Sodium, Week 44, n=258, 263 | 139.5 ± 1.95 | 139.6 ± 1.79 |
| Sodium, Week 48, n=247, 262 | 139.4 ± 1.68 | 139.5 ± 1.75 |
| Urea, Baseline (Day 1), n=283, 283 | 5.30 ± 1.468 | 5.17 ± 1.458 |
| Urea, Week 4, n=280, 277 | 5.33 ± 1.424 | 5.14 ± 1.508 |
| Urea, Week 8, n=212, 278 | 5.32 ± 1.485 | 5.12 ± 1.480 |
| Urea, Week 12, n=270, 276 | 5.28 ± 1.424 | 5.20 ± 1.574 |
| Urea, Week 16, n=255, 269 | 5.26 ± 1.385 | 5.20 ± 1.561 |
| Urea, Week 20, n=260, 272 | 5.18 ± 1.349 | 5.22 ± 1.483 |
| Urea, Week 24, n=261, 268 | 5.38 ± 1.489 | 5.11 ± 1.449 |
| Urea, Week 28, n=253, 268 | 5.32 ± 1.422 | 5.21 ± 1.406 |
| Urea, Week 32, n=255, 268 | 5.43 ± 1.440 | 5.17 ± 1.491 |
| Urea, Week 36, n=254, 261 | 5.31 ± 1.396 | 5.23 ± 1.556 |
| Urea, Week 40, n=250, 266 | 5.40 ± 1.523 | 5.26 ± 1.566 |
| Urea, Week 44, n=258, 263 | 5.38 ± 1.543 | 5.24 ± 1.512 |
| Urea, Week 48, n=247, 262 | 5.37 ± 1.402 | 5.27 ± 2.305 |
Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated timepoints.
| Units per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), n=283, 283 | 31.0 ± 21.04 | 30.9 ± 28.89 |
| Week 4, n=278, 276 | 31.7 ± 27.17 | 32.6 ± 24.73 |
| Week 8, n=211, 278 | 31.5 ± 21.15 | 31.3 ± 19.96 |
| Week 12, n=270, 276 | 31.4 ± 23.94 | 33.6 ± 23.37 |
| Week 16, n=254, 269 | 30.8 ± 22.39 | 32.1 ± 18.99 |
| Week 20, n=260, 270 | 31.3 ± 23.46 | 31.9 ± 19.13 |
| Week 24, n=260, 268 | 31.3 ± 22.60 | 32.2 ± 21.08 |
| Week 28, n=253, 268 | 30.3 ± 18.71 | 33.0 ± 22.56 |
| Week 32, n=254, 268 | 33.5 ± 35.38 | 33.2 ± 32.95 |
| Week 36, n=254, 261 | 31.5 ± 20.49 | 31.2 ± 20.03 |
| Week 40, n=250, 266 | 32.6 ± 27.07 | 32.1 ± 22.19 |
| Week 44, n=258, 263 | 36.3 ± 45.04 | 33.0 ± 24.09 |
| Week 48, n=247, 261 | 30.1 ± 20.31 | 32.6 ± 28.96 |
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
| mL/min/1.73/m^2 | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), n=283, 283 | 94.3 ± 17.61 | 97.9 ± 17.70 |
| Week 4, n=278, 277 | 101.2 ± 16.56 | 96.5 ± 17.14 |
| Week 8, n=211, 278 | 104.9 ± 15.64 | 98.1 ± 17.46 |
| Week 12, n=270, 276 | 104.8 ± 16.08 | 98.6 ± 17.77 |
| Week 16, n=254, 269 | 104.2 ± 15.03 | 97.6 ± 16.84 |
| Week 20, n=261, 271 | 105.5 ± 15.19 | 98.0 ± 17.67 |
| Week 24, n=261, 268 | 105.1 ± 16.05 | 97.9 ± 17.33 |
| Week 28, n=253, 268 | 105.3 ± 16.18 | 98.8 ± 17.40 |
| Week 32, n=254, 268 | 105.1 ± 16.10 | 98.8 ± 17.39 |
| Week 36, n=254, 262 | 104.7 ± 15.88 | 98.0 ± 16.60 |
| Week 40, n=250, 266 | 104.3 ± 16.47 | 98.3 ± 17.25 |
| Week 44, n=258, 263 | 104.4 ± 16.73 | 98.9 ± 16.67 |
| Week 48, n=247, 261 | 103.6 ± 16.34 | 96.9 ± 18.21 |
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.
| Millimoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Total Cholesterol, Baseline (Day 1), n=268, 275 | 4.44 ± 0.928 | 4.42 ± 0.986 |
| Total Cholesterol, Week 48, n=240, 239 | 4.65 ± 1.021 | 4.46 ± 0.944 |
| HDL cholesterol, Baseline (Day 1), n=268, 275 | 1.249 ± 0.3761 | 1.302 ± 0.3851 |
| HDL cholesterol, Week 48, n=240, 239 | 1.359 ± 0.4096 | 1.376 ± 0.4335 |
| LDL cholesterol, Baseline (Day 1), n=267, 275 | 2.557 ± 0.7991 | 2.529 ± 0.7870 |
| LDL cholesterol, Week 48, n=238, 237 | 2.697 ± 0.9158 | 2.472 ± 0.7693 |
| Triglycerides, Baseline (Day 1), n=268, 275 | 1.387 ± 0.9142 | 1.294 ± 0.7392 |
| Triglycerides, Week 48, n=240, 239 | 1.323 ± 0.9333 | 1.341 ± 0.9059 |
The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to DAIDS scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Urine bilirubin,Baseline (Day 1),Trace, n=276, 276 | 0 | 0 |
| Urine bilirubin, Baseline (Day 1), 1+, n=276, 276 | 15 | 22 |
| Urine bilirubin, Baseline (Day 1), 2+, n=276, 276 | 0 | 1 |
| Urine bilirubin, Baseline (Day 1), 3+, n=276, 276 | 0 | 0 |
| Urine glucose, Baseline (Day 1), Trace, n=282, 282 | 0 | 1 |
| Urine glucose, Baseline (Day 1), 1+, n=282, 282 | 2 | 0 |
| Urine glucose, Baseline (Day 1), 2+, n=282, 282 | 0 | 0 |
| Urine glucose, Baseline (Day 1), 3+, n=282, 282 | 1 | 1 |
| Urine ketones, Baseline (Day 1), Trace, n=276, 276 | 30 | 29 |
| Urine ketones, Baseline (Day 1), 1+, n=276, 276 | 4 | 2 |
| Urine ketones, Baseline (Day 1), 2+, n=276, 276 | 0 | 1 |
| Urine ketones, Baseline (Day 1), 3+, n=276, 276 | 0 | 0 |
| Urine leukocyte esterase,Baseline,Trace,n=276, 276 | 22 | 21 |
| Urine leukocyte esterase, Baseline, 1+, n=276, 276 | 12 | 14 |
| Urine leukocyte esterase, Baseline, 2+, n=276, 276 | 9 | 9 |
| Urine leukocyte esterase, Baseline, 3+, n=276, 276 | 3 | 3 |
| Urine nitrite, Baseline, positive, n=276, 276 | 6 | 9 |
| Urine occult blood, Baseline, Trace, n=276, 276 | 13 | 9 |
| Urine occult blood, Baseline, 1+, n=276, 276 | 5 | 6 |
| Urine occult blood, Baseline, 2+, n=276, 276 | 6 | 3 |
| Urine occult blood, Baseline, 3+, n=276, 276 | 3 | 2 |
| Urine protein, Baseline, Trace, n=276, 276 | 25 | 20 |
| Urine protein, Baseline, 1+, n=276, 276 | 4 | 10 |
| Urine protein, Baseline, 2+, n=276, 276 | 3 | 7 |
| Urine protein, Baseline, 3+, n=276, 276 | 0 | 0 |
| Urine bilirubin, Week 4, Trace, n=278, 272 | 0 | 0 |
| Urine bilirubin, Week 4, 1+, n=278, 272 | 14 | 28 |
| Urine bilirubin, Week 4, 2+, n=278, 272 | 0 | 0 |
| Urine bilirubin, Week 4, 3+, n=278, 272 | 0 | 0 |
| Urine glucose, Week 4, Trace, n=278, 272 | 0 | 0 |
| Urine glucose, Week 4, 1+, n=278, 272 | 0 | 2 |
| Urine glucose, Week 4, 2+, n=278, 272 | 0 | 0 |
| Urine glucose, Week 4, 3+, n=278, 272 | 1 | 0 |
| Urine ketones, Week 4, Trace, n=278, 272 | 20 | 21 |
| Urine ketones, Week 4, 1+, n=278, 272 | 1 | 5 |
| Urine ketones, Week 4, 2+, n=278, 272 | 0 | 0 |
| Urine ketones, Week 4, 3+, n=278, 272 | 1 | 0 |
| Urine leukocyte esterase, Week 4, Trace,n=278, 272 | 19 | 23 |
| Urine leukocyte esterase, Week 4, 1+, n=278, 272 | 9 | 17 |
| Urine leukocyte esterase, Week 4, 2+, n=278, 272 | 6 | 6 |
| Urine leukocyte esterase, Week 4, 3+, n=278, 272 | 2 | 4 |
| Urine nitrite, Week 4, positive, n=278, 272 | 2 | 10 |
| Urine occult blood, Week 4, Trace, n=278, 272 | 11 | 13 |
| Urine occult blood, Week 4, 1+, n=278, 272 | 8 | 3 |
| Urine occult blood, Week 4, 2+, n=278, 272 | 5 | 1 |
| Urine occult blood, Week 4, 3+, n=278, 272 | 0 | 6 |
| Urine protein, Week 4, Trace, n=278, 272 | 12 | 24 |
| Urine protein, Week 4, 1+, n=278, 272 | 4 | 11 |
| Urine protein, Week 4, 2+, n=278, 272 | 1 | 3 |
| Urine protein, Week 4, 3+, n=278, 272 | 1 | 1 |
| Urine bilirubin, Week 24, Trace, n=195, 258 | 0 | 0 |
| Urine bilirubin, Week 24, 1+, n=195, 258 | 7 | 14 |
| , Urine bilirubin, Week 24, 2+, n=195, 258 | 0 | 0 |
| Urine bilirubin, Week 24, 3+, n=195, 258 | 0 | 0 |
| Urine glucose, Week 24, Trace, n=195, 258 | 0 | 0 |
| Urine glucose, Week 24, 1+, n=195, 258 | 0 | 0 |
| Urine glucose, Week 24, 2+, n=195, 258 | 1 | 0 |
| Urine glucose, Week 24, 3+, n=195, 258 | 1 | 1 |
| Urine ketones, Week 24, Trace, n=195, 258 | 13 | 9 |
| Urine ketones, Week 24, 1+, n=195, 258 | 0 | 2 |
| Urine ketones, Week 24, 2+, n=195, 258 | 0 | 0 |
| Urine ketones, Week 24, 3+, n=195, 258 | 0 | 0 |
| Urine leukocyte esterase,Week 24, Trace,n=195, 258 | 15 | 28 |
| Urine leukocyte esterase, Week 24, 1+, n=195, 258 | 8 | 12 |
| Urine leukocyte esterase, Week 24, 2+, n=195, 258 | 3 | 10 |
| Urine leukocyte esterase, Week 24, 3+, n=195, 258 | 1 | 3 |
| Urine nitrite, Week 24, positive, n=195, 258 | 4 | 5 |
| Urine occult blood, Week 24, Trace, n=195, 258 | 9 | 9 |
| Urine occult blood, Week 24, 1+, n=195, 258 | 3 | 8 |
| Urine occult blood, Week 24, 2+, n=195, 258 | 3 | 2 |
| Urine occult blood, Week 24, 3+, n=195, 258 | 1 | 3 |
| Urine protein, Week 24, Trace, n=195, 258 | 11 | 21 |
| Urine protein, Week 24, 1+, n=195, 258 | 4 | 7 |
| Urine protein, Week 24, 2+, n=195, 258 | 2 | 4 |
| Urine protein, Week 24, 3+, n=195, 258 | 0 | 1 |
| Urine bilirubin, Week 48, Trace, n=261, 259 | 0 | 0 |
| Urine bilirubin, Week 48, 1+, n=261, 259 | 9 | 12 |
| Urine bilirubin, Week 48, 2+, n=261, 259 | 0 | 0 |
| Urine bilirubin, Week 48, 3+, n=261, 259 | 0 | 1 |
| Urine glucose, Week 48, Trace, n=261, 259 | 0 | 0 |
| Urine glucose, Week 48, 1+, n=261, 259 | 1 | 0 |
| Urine glucose, Week 48, 2+, n=261, 259 | 0 | 0 |
| Urine glucose, Week 48, 3+, n=261, 259 | 2 | 0 |
| Urine ketones, Week 48, Trace, n=261, 259 | 12 | 13 |
| Urine ketones, Week 48, 1+, n=261, 259 | 0 | 4 |
| Urine ketones, Week 48, 2+, n=261, 259 | 0 | 0 |
| Urine ketones, Week 48, 3+, n=261, 259 | 0 | 0 |
| Urine leukocyte esterase, Week 48,Trace,n=261, 259 | 12 | 15 |
| Urine leukocyte esterase, Week 48, 1+, n=261, 259 | 5 | 10 |
| Urine leukocyte esterase, Week 48, 2+, n=261, 259 | 4 | 7 |
| Urine leukocyte esterase, Week 48, 3+, n=261, 259 | 2 | 2 |
| Urine nitrite, Week 48, positive, n=261, 259 | 2 | 6 |
| Urine occult blood, Week 48, Trace, n=261, 259 | 9 | 8 |
| Urine occult blood, Week 48, 1+, n=261, 259 | 4 | 6 |
| Urine occult blood, Week 48, 2+, n=261, 259 | 8 | 3 |
| Urine occult blood, Week 48, 3+, n=261, 259 | 1 | 0 |
| Urine protein, Week 48, Trace, n=261, 259 | 14 | 23 |
| Urine protein, Week 48, 1+, n=261, 259 | 5 | 8 |
| Urine protein, Week 48, 2+, n=261, 259 | 6 | 6 |
| Urine protein, Week 48, 3+, n=261, 259 | 0 | 0 |
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Baseline (Day 1), pH=5, n=276, 276 | 36 | 32 |
| Baseline (Day 1), pH=5.5, n=276, 276 | 104 | 101 |
| Baseline (Day 1), pH=6, n=276, 276 | 66 | 62 |
| Baseline (Day 1), pH=6.5, n=276, 276 | 29 | 35 |
| Baseline (Day 1), pH=7, n=276, 276 | 27 | 27 |
| Baseline (Day 1), pH=7.5, n=276, 276 | 7 | 12 |
| Baseline (Day 1), pH=8, n=276, 276 | 4 | 4 |
| Baseline (Day 1), pH=8.5, n=276, 276 | 2 | 1 |
| Baseline (Day 1), pH>9.0, n=276, 276 | 1 | 2 |
| Week 4, pH=5, n=278, 272 | 33 | 41 |
| Week 4, pH=5.5, n=278, 272 | 83 | 81 |
| Week 4, pH=6, n=278, 272 | 68 | 71 |
| Week 4, pH=6.5, n=278, 272 | 48 | 36 |
| Week 4, pH=7, n=278, 272 | 25 | 22 |
| Week 4, pH=7.5, n=278, 272 | 10 | 12 |
| Week 4, pH=8, n=278, 272 | 5 | 5 |
| Week 4, pH=8.5, n=278, 272 | 6 | 1 |
| Week 4, pH>9.0, n=278, 272 | 0 | 3 |
| Week 24, pH=5, n=195, 258 | 42 | 50 |
| Week 24, pH=5.5, n=195, 258 | 55 | 78 |
| Week 24, pH=6, n=195, 258 | 47 | 51 |
| Week 24, pH=6.5, n=195, 258 | 19 | 46 |
| Week 24, pH=7, n=195, 258 | 22 | 16 |
| Week 24, pH=7.5, n=195, 258 | 4 | 13 |
| Week 24, pH=8, n=195, 258 | 3 | 2 |
| Week 24, pH=8.5, n=195, 258 | 3 | 1 |
| Week 24, pH>9.0, n=195, 258 | 0 | 1 |
| Week 48, pH=5, n=261, 259 | 54 | 57 |
| Week 48, pH=5.5, n=261, 259 | 81 | 77 |
| Week 48, pH=6, n=261, 259 | 50 | 61 |
| Week 48, pH=6.5, n=261, 259 | 30 | 27 |
| Week 48, pH=7, n=261, 259 | 24 | 18 |
| Week 48, pH=7.5, n=261, 259 | 14 | 10 |
| Week 48, pH=8, n=261, 259 | 5 | 4 |
| Week 48, pH=8.5, n=261, 259 | 2 | 3 |
| Week 48, pH>9.0, n=261, 259 | 1 | 2 |
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^9 cells per Liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Basophils, Week 4, n=277, 270 | 0.002 ± 0.0155 | 0.002 ± 0.0155 |
| Basophils, Week 8, n=210, 272 | 0.002 ± 0.0161 | 0.001 ± 0.0153 |
| Basophils, Week 12, n=267, 272 | 0.003 ± 0.0181 | 0.001 ± 0.0157 |
| Basophils, Week 16, n=247, 259 | 0.008 ± 0.0215 | 0.006 ± 0.0227 |
| Basophils, Week 20, n=247, 259 | 0.013 ± 0.0250 | 0.010 ± 0.0271 |
| Basophils, Week 24, n=256, 260 | 0.015 ± 0.0247 | 0.014 ± 0.0269 |
| Basophils, Week 28, n=239, 258 | 0.017 ± 0.0265 | 0.016 ± 0.0251 |
| Basophils, Week 32, n=246, 263 | 0.022 ± 0.0266 | 0.017 ± 0.0227 |
| Basophils, Week 36, n=250, 259 | 0.021 ± 0.0235 | 0.018 ± 0.0249 |
| Basophils, Week 40, n=244, 245 | 0.020 ± 0.0252 | 0.019 ± 0.0243 |
| Basophils, Week 44, n=249, 260 | 0.018 ± 0.0246 | 0.018 ± 0.0265 |
| Basophils, Week 48, n=239, 258 | 0.016 ± 0.0218 | 0.016 ± 0.0243 |
| Eosinophils, Week 4, n=277, 270 | 0.024 ± 0.1099 | 0.013 ± 0.1220 |
| Eosinophils, Week 8, n=210, 272 | 0.023 ± 0.1101 | 0.009 ± 0.1075 |
| Eosinophils, Week 12, n=267, 272 | 0.023 ± 0.1305 | 0.018 ± 0.1082 |
| Eosinophils, Week 16, n=247, 259 | 0.037 ± 0.1425 | 0.022 ± 0.1262 |
| Eosinophils, Week 20, n=247, 259 | 0.044 ± 0.1478 | 0.027 ± 0.1288 |
| Eosinophils, Week 24, n=256, 260 | 0.051 ± 0.1307 | 0.030 ± 0.1124 |
| Eosinophils, Week 28, n=239, 258 | 0.061 ± 0.1367 | 0.037 ± 0.1393 |
| Eosinophils, Week 32, n=246, 263 | 0.061 ± 0.1556 | 0.029 ± 0.1158 |
| Eosinophils, Week 36, n=250, 259 | 0.070 ± 0.1797 | 0.030 ± 0.1303 |
| Eosinophils, Week 40, n=244, 245 | 0.062 ± 0.1623 | 0.035 ± 0.1155 |
| Eosinophils, Week 44, n=249, 260 | 0.057 ± 0.1598 | 0.038 ± 0.1410 |
| Eosinophils, Week 48, n=239, 258 | 0.039 ± 0.1416 | 0.030 ± 0.1183 |
| Leukocytes, Week 4, n=279, 272 | 0.57 ± 1.404 | 0.42 ± 1.383 |
| Leukocytes, Week 8, n=211, 275 | 0.18 ± 1.278 | 0.32 ± 1.374 |
| Leukocytes, Week 12, n=270, 275 | 0.07 ± 1.402 | 0.40 ± 1.465 |
| Leukocytes, Week 16, n=252, 265 | 0.32 ± 1.641 | 0.41 ± 1.621 |
| Leukocytes, Week 20, n=254, 265 | 0.27 ± 1.505 | 0.44 ± 1.480 |
| Leukocytes, Week 24, n=258, 264 | 0.34 ± 1.581 | 0.45 ± 1.725 |
| Leukocytes, Week 28, n=244, 263 | 0.34 ± 1.713 | 0.48 ± 1.551 |
| Leukocytes, Week 32, n=253, 266 | 0.28 ± 1.726 | 0.42 ± 1.748 |
| Leukocytes, Week 36, n=252, 259 | 0.34 ± 1.549 | 0.52 ± 1.789 |
| Leukocytes, Week 40, n=246, 253 | 0.16 ± 1.497 | 0.42 ± 1.614 |
| Leukocytes, Week 44, n=256, 262 | 0.22 ± 1.732 | 0.49 ± 1.626 |
| Leukocytes, Week 48, n=243, 260 | 0.09 ± 1.455 | 0.29 ± 1.520 |
| Lymphocytes, Week 4, n=277, 270 | 0.198 ± 0.5156 | 0.231 ± 0.5066 |
| Lymphocytes, Week 8, n=210, 272 | 0.054 ± 0.4812 | 0.155 ± 0.5088 |
| Lymphocytes, Week 12, n=267, 272 | 0.012 ± 0.4632 | 0.164 ± 0.5560 |
| Lymphocytes, Week 16, n=247, 259 | 0.020 ± 0.4971 | 0.158 ± 0.5246 |
| Lymphocytes, Week 20, n=247, 259 | 0.030 ± 0.4889 | 0.146 ± 0.5292 |
| Lymphocytes, Week 24, n=256, 260 | 0.014 ± 0.5195 | 0.148 ± 0.5716 |
| Lymphocytes, Week 28, n=239, 258 | 0.021 ± 0.5389 | 0.145 ± 0.5469 |
| Lymphocytes, Week 32, n=246, 263 | 0.021 ± 0.5195 | 0.129 ± 0.5812 |
| Lymphocytes, Week 36, n=250, 259 | 0.028 ± 0.5261 | 0.132 ± 0.5258 |
| Lymphocytes, Week 40, n=244, 245 | 0.006 ± 0.5303 | 0.054 ± 0.5106 |
| Lymphocytes, Week 44, n=249, 260 | -0.021 ± 0.6176 | 0.098 ± 0.5139 |
| Lymphocytes, Week 48, n=239, 258 | -0.074 ± 0.5191 | 0.039 ± 0.5936 |
| Monocytes, Week 4, n=277, 270 | 0.038 ± 0.1269 | 0.031 ± 0.1528 |
| Monocytes, Week 8, n=210, 272 | 0.022 ± 0.1464 | 0.013 ± 0.1600 |
| Monocytes, Week 12, n=267, 272 | 0.016 ± 0.1234 | 0.018 ± 0.1613 |
| Monocytes, Week 16, n=247, 259 | 0.059 ± 0.1548 | 0.035 ± 0.1618 |
| Monocytes, Week 20, n=247, 259 | 0.070 ± 0.1583 | 0.053 ± 0.1790 |
| Monocytes, Week 24, n=256, 260 | 0.059 ± 0.1442 | 0.070 ± 0.1599 |
| Monocytes, Week 28, n=239, 258 | 0.086 ± 0.1584 | 0.077 ± 0.1806 |
| Monocytes, Week 32, n=246, 263 | 0.081 ± 0.1530 | 0.088 ± 0.1841 |
| Monocytes, Week 36, n=250, 259 | 0.084 ± 0.1685 | 0.086 ± 0.1772 |
| Monocytes, Week 40, n=244, 245 | 0.056 ± 0.1378 | 0.076 ± 0.1651 |
| Monocytes, Week 44, n=249, 260 | 0.062 ± 0.1522 | 0.057 ± 0.1558 |
| Monocytes, Week 48, n=239, 258 | 0.024 ± 0.1395 | 0.031 ± 0.1389 |
| Neutrophils, Week 4, n=277, 270 | 0.313 ± 1.3508 | 0.130 ± 1.1869 |
| Neutrophils, Week 8, n=210, 272 | 0.084 ± 1.1310 | 0.125 ± 1.2775 |
| Neutrophils, Week 12, n=267, 272 | 0.032 ± 1.3016 | 0.185 ± 1.3016 |
| Neutrophils, Week 16, n=247, 259 | 0.215 ± 1.5752 | 0.211 ± 1.4233 |
| Neutrophils, Week 20, n=247, 259 | 0.132 ± 1.4116 | 0.217 ± 1.3130 |
| Neutrophils, Week 24, n=256, 260 | 0.218 ± 1.4890 | 0.217 ± 1.4694 |
| Neutrophils, Week 28, n=239, 258 | 0.193 ± 1.5833 | 0.221 ± 1.3274 |
| Neutrophils, Week 32, n=246, 263 | 0.144 ± 1.5739 | 0.175 ± 1.5009 |
| Neutrophils, Week 36, n=250, 259 | 0.170 ± 1.3865 | 0.243 ± 1.4938 |
| Neutrophils, Week 40, n=244, 245 | 0.055 ± 1.4372 | 0.259 ± 1.4739 |
| Neutrophils, Week 44, n=249, 260 | 0.156 ± 1.5382 | 0.273 ± 1.4445 |
| Neutrophils, Week 48, n=239, 258 | 0.110 ± 1.3697 | 0.201 ± 1.3169 |
| Platelets, Week 4, n=278, 269 | 5.7 ± 29.10 | 4.3 ± 31.11 |
| Platelets, Week 8, n=207, 273 | -0.9 ± 29.09 | 2.2 ± 35.14 |
| Platelets, Week 12, n=269, 271 | 0.8 ± 32.49 | 6.2 ± 36.23 |
| Platelets, Week 16, n=251, 263 | 1.6 ± 33.34 | 9.3 ± 51.53 |
| Platelets, Week 20, n=255, 264 | 7.6 ± 38.18 | 13.4 ± 39.24 |
| Platelets, Week 24, n=256, 261 | 6.5 ± 36.11 | 14.4 ± 35.15 |
| Platelets, Week 28, n=245, 258 | 8.6 ± 38.23 | 18.4 ± 38.56 |
| Platelets, Week 32, n=249, 262 | 7.9 ± 40.22 | 14.6 ± 34.28 |
| Platelets, Week 36, n=248, 259 | 12.1 ± 38.48 | 18.6 ± 35.81 |
| Platelets, Week 40, n=244, 254 | 8.2 ± 36.08 | 17.7 ± 43.30 |
| Platelets, Week 44, n=254, 261 | 9.4 ± 38.42 | 19.3 ± 47.64 |
| Platelets, Week 48, n=240, 255 | 7.7 ± 39.61 | 16.4 ± 47.45 |
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Femtoliters | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=279, 273 | -0.7 ± 1.66 | 0.2 ± 1.56 |
| Week 8, n=211, 275 | -2.5 ± 2.33 | 0.2 ± 2.06 |
| Week 12, n=270, 275 | -3.8 ± 2.49 | -0.3 ± 2.48 |
| Week 16, n=254, 265 | -5.1 ± 2.63 | -0.2 ± 2.65 |
| Week 20, n=255, 267 | -5.6 ± 2.72 | -0.5 ± 2.55 |
| Week 24, n=259, 264 | -5.6 ± 2.85 | -0.5 ± 2.58 |
| Week 28, n=246, 265 | -5.6 ± 2.97 | -0.9 ± 2.52 |
| Week 32, n=254, 267 | -5.3 ± 3.02 | -0.9 ± 2.55 |
| Week 36, n=252, 261 | -5.3 ± 3.00 | -0.6 ± 2.45 |
| Week 40, n=246, 255 | -4.8 ± 3.02 | -0.1 ± 2.64 |
| Week 44, n=256, 262 | -4.2 ± 3.12 | 0.2 ± 2.81 |
| Week 48, n=243, 260 | -3.7 ± 3.12 | 1.0 ± 2.93 |
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^12 cells per Liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=279, 273 | 0.08 ± 0.226 | -0.03 ± 0.228 |
| Week 8, n=211, 275 | 0.18 ± 0.249 | 0.02 ± 0.239 |
| Week 12, n=270, 275 | 0.23 ± 0.269 | 0.01 ± 0.273 |
| Week 16, n=254, 265 | 0.30 ± 0.263 | 0.01 ± 0.255 |
| Week 20, n=255, 267 | 0.31 ± 0.272 | -0.01 ± 0.242 |
| Week 24, n=259, 264 | 0.31 ± 0.254 | 0.02 ± 0.242 |
| Week 28, n=246, 265 | 0.29 ± 0.248 | 0.04 ± 0.259 |
| Week 32, n=254, 267 | 0.25 ± 0.283 | 0.01 ± 0.259 |
| Week 36, n=252, 261 | 0.23 ± 0.263 | -0.01 ± 0.250 |
| Week 40, n=246, 255 | 0.23 ± 0.246 | -0.01 ± 0.239 |
| Week 44, n=256, 262 | 0.21 ± 0.234 | -0.06 ± 0.243 |
| Week 48, n=243, 260 | 0.16 ± 0.264 | -0.06 ± 0.257 |
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Proportion of red blood cells in blood | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=279, 273 | 0.0046 ± 0.02082 | -0.0013 ± 0.02213 |
| Week 8, n=211, 275 | 0.0053 ± 0.02344 | 0.0026 ± 0.02314 |
| Week 12, n=270, 275 | 0.0040 ± 0.02383 | -0.0000 ± 0.02618 |
| Week 16, n=254, 265 | 0.0035 ± 0.02338 | -0.0003 ± 0.02489 |
| Week 20, n=255, 267 | 0.0024 ± 0.02335 | -0.0033 ± 0.02323 |
| Week 24, n=259, 264 | 0.0021 ± 0.02299 | -0.0012 ± 0.02337 |
| Week 28, n=246, 265 | -0.0003 ± 0.02262 | -0.0001 ± 0.02460 |
| Week 32, n=254, 267 | -0.0017 ± 0.02607 | -0.0032 ± 0.02503 |
| Week 36, n=252, 261 | -0.0041 ± 0.02515 | -0.0032 ± 0.02407 |
| Week 40, n=246, 255 | -0.0014 ± 0.02461 | -0.0017 ± 0.02388 |
| Week 44, n=256, 262 | -0.0011 ± 0.02230 | -0.0045 ± 0.02328 |
| Week 48, n=243, 260 | -0.0027 ± 0.02571 | -0.0019 ± 0.02572 |
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Grams per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=279, 273 | 1.8 ± 6.59 | 0.1 ± 6.47 |
| Week 8, n=211, 275 | 1.9 ± 7.29 | 1.3 ± 7.26 |
| Week 12, n=270, 275 | 2.1 ± 7.47 | 1.5 ± 8.28 |
| Week 16, n=254, 265 | 2.9 ± 6.98 | 1.4 ± 7.88 |
| Week 20, n=255, 267 | 2.9 ± 7.43 | 1.4 ± 7.18 |
| Week 24, n=259, 264 | 2.7 ± 7.32 | 2.0 ± 7.11 |
| Week 28, n=246, 265 | 2.7 ± 6.80 | 3.3 ± 7.75 |
| Week 32, n=254, 267 | 2.7 ± 8.08 | 2.9 ± 7.73 |
| Week 36, n=252, 261 | 2.0 ± 7.93 | 2.8 ± 7.73 |
| Week 40, n=246, 255 | 3.2 ± 7.91 | 3.1 ± 7.85 |
| Week 44, n=256, 262 | 2.5 ± 7.66 | 1.8 ± 7.62 |
| Week 48, n=243, 260 | 1.4 ± 7.98 | 2.1 ± 8.33 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| International units per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| ALT, Week 4, n=281, 277 | 3.7 ± 49.90 | -1.4 ± 11.14 |
| ALT, Week 8, n=212, 278 | 1.0 ± 14.28 | -0.9 ± 11.86 |
| ALT, Week 12, n=270, 276 | 1.0 ± 15.80 | -0.1 ± 13.27 |
| ALT, Week 16, n=255, 269 | 1.2 ± 16.61 | 1.5 ± 13.99 |
| ALT, Week 20, n=260, 272 | 5.3 ± 72.80 | 0.2 ± 17.04 |
| ALT, Week 24, n=261, 268 | 3.3 ± 30.00 | -0.4 ± 12.75 |
| ALT, Week 28, n=253, 268 | 1.9 ± 18.82 | 0.2 ± 12.72 |
| ALT, Week 32, n=256, 268 | 18.1 ± 293.85 | -0.4 ± 13.08 |
| ALT, Week 36, n=255, 261 | -0.1 ± 14.10 | 1.7 ± 32.63 |
| ALT, Week 40, n=250, 266 | 0.6 ± 17.42 | 0.0 ± 14.84 |
| ALT, Week 44, n=258, 263 | 1.7 ± 27.55 | 0.8 ± 16.75 |
| ALT, Week 48, n=247, 262 | -0.2 ± 22.91 | 0.1 ± 18.81 |
| ALP, Week 4, n=281, 277 | 0.3 ± 11.04 | -1.3 ± 15.74 |
| ALP, Week 8, n=212, 278 | 0.6 ± 10.41 | -0.5 ± 17.00 |
| ALP, Week 12, n=270, 276 | 1.4 ± 12.71 | -0.7 ± 17.40 |
| ALP, Week 16, n=255, 269 | 0.8 ± 10.34 | -0.3 ± 17.99 |
| ALP, Week 20, n=260, 272 | 1.5 ± 10.20 | -1.1 ± 17.35 |
| ALP, Week 24, n=261, 268 | 1.2 ± 9.57 | -0.7 ± 17.03 |
| ALP, Week 28, n=253, 268 | 1.4 ± 10.57 | 0.6 ± 17.28 |
| ALP, Week 32, n=256, 268 | 1.9 ± 15.42 | -0.3 ± 18.11 |
| ALP, Week 36, n=255, 261 | 3.3 ± 20.31 | 1.3 ± 20.90 |
| ALP, Week 40, n=250, 266 | 1.8 ± 9.84 | 0.7 ± 18.50 |
| ALP, Week 44, n=258, 263 | 1.4 ± 11.00 | 1.2 ± 17.62 |
| ALP, Week 48, n=247, 262 | 1.1 ± 12.75 | 0.7 ± 17.54 |
| AST, Week 4, n=281, 277 | 1.5 ± 24.47 | -1.6 ± 14.58 |
| AST, Week 8, n=212, 278 | 0.7 ± 19.90 | -2.0 ± 14.13 |
| AST, Week 12, n=270, 276 | -0.3 ± 10.74 | -1.5 ± 15.34 |
| AST, Week 16, n=255, 269 | -0.1 ± 11.31 | 1.0 ± 16.68 |
| AST, Week 20, n=260, 272 | 2.3 ± 32.28 | 0.2 ± 26.46 |
| AST, Week 24, n=261, 268 | 2.8 ± 24.22 | -1.5 ± 16.00 |
| AST, Week 28, n=253, 268 | 1.7 ± 15.85 | -0.9 ± 16.99 |
| AST, Week 32, n=256, 268 | 14.0 ± 233.48 | -1.9 ± 14.68 |
| AST, Week 36, n=255, 261 | -0.1 ± 12.22 | -0.2 ± 22.03 |
| AST, Week 40, n=250, 266 | 0.2 ± 13.31 | -1.5 ± 15.24 |
| AST, Week 44, n=258, 263 | 1.3 ± 16.49 | -0.5 ± 18.31 |
| AST Week 48, n=247, 262 | -0.8 ± 11.88 | 0.8 ± 44.70 |
| CK, Week 4, n=280, 277 | 31.1 ± 456.63 | -27.0 ± 523.89 |
| CK, Week 8, n=212, 278 | 53.5 ± 907.83 | -46.6 ± 499.91 |
| CK, Week 12, n=270, 276 | 1.2 ± 420.32 | -17.2 ± 605.92 |
| CK, Week 16, n=255, 269 | -18.0 ± 316.74 | 40.2 ± 746.32 |
| CK, Week 20, n=260, 272 | 19.2 ± 536.70 | 57.3 ± 1208.73 |
| CK, Week 24, n=261, 268 | 47.3 ± 635.42 | -19.6 ± 605.13 |
| CK, Week 28, n=253, 268 | 49.9 ± 669.37 | -8.5 ± 705.35 |
| CK, Week 32, n=256, 268 | -24.5 ± 298.70 | -42.5 ± 509.77 |
| CK, Week 36, n=254, 261 | 14.7 ± 515.62 | 12.2 ± 674.76 |
| CK, Week 40, n=250, 266 | 24.8 ± 544.72 | -51.7 ± 497.70 |
| CK, Week 44, n=258, 263 | 54.8 ± 526.28 | -20.1 ± 652.24 |
| CK, Week 48, n=247, 262 | -17.8 ± 309.33 | 121.1 ± 2682.33 |
Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Grams per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=280, 277 | -0.1 ± 2.15 | -0.3 ± 2.14 |
| Week 8, n=212, 278 | -0.1 ± 2.32 | -0.3 ± 2.25 |
| Week 12, n=270, 276 | -0.1 ± 2.38 | 0.0 ± 2.58 |
| Week 16, n=255, 269 | 0.2 ± 2.23 | -0.1 ± 2.48 |
| Week 20, n=260, 272 | 0.2 ± 2.51 | -0.2 ± 2.47 |
| Week 24, n=261, 268 | 0.5 ± 2.28 | 0.2 ± 2.37 |
| Week 28, n=253, 268 | 0.5 ± 2.42 | 0.4 ± 2.32 |
| Week 32, n=255, 268 | 0.7 ± 2.47 | 0.4 ± 2.60 |
| Week 36, n=254, 261 | 0.3 ± 2.44 | 0.3 ± 2.52 |
| Week 40, n=250, 266 | 0.9 ± 2.42 | 0.5 ± 2.46 |
| Week 44, n=258, 263 | 0.9 ± 2.44 | 0.4 ± 2.49 |
| Week 48, n=247, 262 | 0.7 ± 2.40 | 0.5 ± 2.63 |
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Micromoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Bilirubin, Week 4, n=281, 277 | 1.4 ± 4.74 | -0.3 ± 3.77 |
| Bilirubin, Week 8, n=212, 278 | 0.9 ± 4.04 | -0.5 ± 4.17 |
| Bilirubin, Week 12, n=270, 276 | 1.2 ± 4.15 | -0.7 ± 4.51 |
| Bilirubin, Week 16, n=255, 269 | 1.2 ± 4.30 | -0.3 ± 3.61 |
| Bilirubin, Week 20, n=260, 272 | 1.1 ± 4.14 | -0.7 ± 4.02 |
| Bilirubin, Week 24, n=261, 268 | 0.8 ± 4.12 | -0.4 ± 3.85 |
| Bilirubin, Week 28, n=253, 268 | 1.2 ± 4.41 | -0.7 ± 3.75 |
| Bilirubin, Week 32, n=256, 268 | 1.3 ± 6.44 | -0.6 ± 4.05 |
| Bilirubin, Week 36, n=255, 260 | 0.6 ± 5.36 | -0.7 ± 4.28 |
| Bilirubin, Week 40, n=250, 266 | 0.9 ± 4.31 | -0.8 ± 4.32 |
| Bilirubin, Week 44, n=258, 263 | 1.2 ± 4.34 | -0.4 ± 4.28 |
| Bilirubin, Week 48, n=247, 262 | 1.1 ± 4.18 | -0.3 ± 4.17 |
| Direct bilirubin, Week 4, n=277, 277 | 0.2 ± 1.40 | -0.1 ± 1.33 |
| Direct bilirubin, Week 8, n=212, 278 | 0.2 ± 1.30 | -0.1 ± 1.19 |
| Direct bilirubin, Week 12, n=269, 273 | 0.2 ± 1.22 | 0.0 ± 1.22 |
| Direct bilirubin, Week 16, n=254, 268 | 0.2 ± 1.44 | -0.1 ± 1.14 |
| Direct bilirubin, Week 20, n=260, 272 | 0.2 ± 1.57 | -0.1 ± 1.14 |
| Direct bilirubin, Week 24, n=260, 266 | 0.1 ± 1.46 | -0.1 ± 1.10 |
| Direct bilirubin, Week 28, n=253, 268 | 0.2 ± 1.26 | -0.1 ± 1.22 |
| Direct bilirubin, Week 32, n=256, 268 | 0.3 ± 3.39 | -0.1 ± 1.08 |
| Direct bilirubin, Week 36, n=255, 260 | 0.1 ± 2.18 | -0.1 ± 1.16 |
| Direct bilirubin, Week 40, n=249, 266 | 0.1 ± 1.42 | -0.1 ± 1.26 |
| Direct bilirubin, Week 44, n=258, 263 | 0.2 ± 1.41 | -0.1 ± 1.19 |
| Direct bilirubin, Week 48, n=247, 262 | 0.0 ± 1.41 | 0.0 ± 1.19 |
| Creatinine, Week 4, n=280, 277 | -6.07 ± 9.696 | 0.61 ± 7.635 |
| Creatinine, Week 8, n=212, 278 | -9.25 ± 9.936 | -0.24 ± 8.838 |
| Creatinine, Week 12, n=270, 276 | -9.89 ± 9.703 | -1.20 ± 8.710 |
| Creatinine, Week 16, n=255, 269 | -9.75 ± 9.572 | -0.33 ± 8.964 |
| Creatinine, Week 20, n=261, 272 | -10.10 ± 9.839 | -0.68 ± 8.700 |
| Creatinine, Week 24, n=262, 268 | -9.73 ± 9.499 | -0.75 ± 8.327 |
| Creatinine, Week 28, n=253, 268 | -10.34 ± 9.731 | -1.33 ± 8.892 |
| Creatinine, Week 32, n=255, 268 | -9.77 ± 9.166 | -1.26 ± 9.243 |
| Creatinine, Week 36, n=254, 262 | -9.57 ± 9.712 | -0.74 ± 8.565 |
| Creatinine, Week 40, n=250, 266 | -9.60 ± 10.656 | -1.10 ± 7.875 |
| Creatinine, Week 44, n=258, 263 | -9.02 ± 9.562 | -1.91 ± 8.306 |
| Creatinine, Week 48, n=247, 262 | -8.97 ± 9.742 | 5.00 ± 85.535 |
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Millimoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| CO2, Week 4, n=280, 276 | 0.6 ± 2.67 | 0.2 ± 2.32 |
| CO2, Week 8, n=212, 278 | 0.2 ± 2.51 | -0.1 ± 2.24 |
| CO2, Week 12, n=270, 276 | 0.2 ± 2.56 | -0.1 ± 2.26 |
| CO2, Week 16, n=255, 269 | 0.4 ± 2.55 | -0.1 ± 2.72 |
| CO2, Week 20, n=260, 272 | 0.3 ± 2.52 | 0.1 ± 2.38 |
| CO2, Week 24, n=261, 268 | 0.6 ± 2.84 | 0.4 ± 2.56 |
| CO2, Week 28, n=253, 268 | 0.5 ± 2.51 | 0.4 ± 2.39 |
| CO2, Week 32, n=255, 268 | 0.5 ± 2.72 | 0.3 ± 2.37 |
| CO2, Week 36, n=253, 261 | 0.7 ± 2.54 | 0.2 ± 2.35 |
| CO2, Week 40, n=249, 265 | 0.4 ± 2.53 | 0.2 ± 2.61 |
| CO2, Week 44, n=257, 263 | 0.4 ± 2.71 | 0.1 ± 2.37 |
| CO2, Week 48, n=247, 262 | 0.0 ± 2.70 | 0.0 ± 2.27 |
| Chloride, Week 4, n=280, 277 | 0.0 ± 2.13 | 0.5 ± 2.17 |
| Chloride, Week 8, n=212, 278 | 0.0 ± 2.05 | 0.3 ± 2.14 |
| Chloride, Week 12, n=270, 276 | 0.0 ± 2.10 | 0.4 ± 2.16 |
| Chloride, Week 16, n=255, 269 | -0.2 ± 2.32 | 0.3 ± 2.39 |
| Chloride, Week 20, n=260, 272 | -0.3 ± 2.49 | 0.4 ± 2.15 |
| Chloride, Week 24, n=261, 268 | -0.2 ± 2.40 | 0.2 ± 2.47 |
| Chloride, Week 28, n=253, 268 | -0.2 ± 2.21 | 0.1 ± 2.18 |
| Chloride, Week 32, n=255, 268 | -0.2 ± 2.37 | 0.3 ± 2.34 |
| Chloride, Week 36, n=254, 261 | -0.1 ± 2.46 | 0.4 ± 2.37 |
| Chloride, Week 40, n=250, 266 | 0.1 ± 2.35 | 0.4 ± 2.20 |
| Chloride, Week 44, n=258, 263 | 0.1 ± 2.40 | 0.7 ± 2.23 |
| Chloride, Week 48, n=247, 262 | 0.0 ± 2.23 | 0.3 ± 2.09 |
| Phosphate, Week 4, n=279, 277 | 0.032 ± 0.1865 | 0.014 ± 0.1771 |
| Phosphate, Week 8, n=212, 278 | -0.016 ± 0.1834 | 0.017 ± 0.1855 |
| Phosphate, Week 12, n=270, 276 | -0.010 ± 0.1825 | 0.009 ± 0.1772 |
| Phosphate, Week 16, n=255, 269 | 0.000 ± 0.1789 | 0.017 ± 0.1892 |
| Phosphate, Week 20, n=260, 272 | -0.029 ± 0.1932 | 0.016 ± 0.1764 |
| Phosphate, Week 24, n=261, 268 | -0.001 ± 0.1907 | 0.011 ± 0.1852 |
| Phosphate, Week 28, n=253, 268 | -0.007 ± 0.1894 | 0.019 ± 0.1882 |
| Phosphate, Week 32, n=255, 268 | -0.004 ± 0.1806 | 0.005 ± 0.2092 |
| Phosphate, Week 36, n=254, 261 | -0.006 ± 0.1798 | 0.021 ± 0.1965 |
| Phosphate, Week 40, n=250, 266 | -0.011 ± 0.1851 | 0.015 ± 0.1753 |
| Phosphate, Week 44, n=258, 263 | -0.004 ± 0.1824 | 0.020 ± 0.1801 |
| Phosphate, Week 48, n=247, 262 | -0.007 ± 0.1784 | 0.020 ± 0.2333 |
| Potassium, Week 4, n=280, 277 | 0.15 ± 0.334 | 0.06 ± 0.368 |
| Potassium, Week 8, n=212, 278 | 0.10 ± 0.348 | 0.08 ± 0.346 |
| Potassium, Week 12, n=270, 276 | 0.09 ± 0.352 | 0.05 ± 0.305 |
| Potassium, Week 16, n=255, 269 | 0.10 ± 0.321 | 0.04 ± 0.314 |
| Potassium, Week 20, n=260, 272 | 0.09 ± 0.374 | 0.04 ± 0.364 |
| Potassium, Week 24, n=261, 268 | 0.12 ± 0.353 | 0.07 ± 0.309 |
| Potassium, Week 28, n=253, 268 | 0.08 ± 0.341 | 0.08 ± 0.350 |
| Potassium, Week 32, n=255, 268 | 0.09 ± 0.334 | 0.06 ± 0.345 |
| Potassium, Week 36, n=254, 261 | 0.10 ± 0.353 | 0.08 ± 0.347 |
| Potassium, Week 40, n=250, 266 | 0.07 ± 0.347 | 0.06 ± 0.345 |
| Potassium, Week 44, n=258, 263 | 0.08 ± 0.353 | 0.06 ± 0.338 |
| Potassium, Week 48, n=247, 262 | 0.01 ± 0.343 | 0.03 ± 0.496 |
| Sodium, Week 4, n=280, 277 | 0.3 ± 2.25 | 0.2 ± 1.95 |
| Sodium, Week 8, n=212, 278 | 0.1 ± 1.98 | 0.1 ± 1.92 |
| Sodium, Week 12, n=270, 276 | 0.3 ± 1.84 | 0.1 ± 1.89 |
| Sodium, Week 16, n=255, 269 | 0.2 ± 2.10 | 0.3 ± 2.21 |
| Sodium, Week 20, n=260, 272 | 0.2 ± 2.08 | 0.4 ± 1.79 |
| Sodium, Week 24, n=261, 268 | 0.2 ± 2.02 | 0.2 ± 2.12 |
| Sodium, Week 28, n=253, 268 | 0.2 ± 1.88 | 0.4 ± 1.82 |
| Sodium, Week 32, n=255, 268 | 0.3 ± 2.13 | 0.3 ± 2.02 |
| Sodium, Week 36, n=254, 261 | 0.2 ± 2.16 | 0.4 ± 1.94 |
| Sodium, Week 40, n=250, 266 | 0.1 ± 2.08 | 0.4 ± 2.13 |
| Sodium, Week 44, n=258, 263 | 0.3 ± 2.30 | 0.4 ± 2.01 |
| Sodium, Week 48, n=247, 262 | 0.2 ± 2.11 | 0.3 ± 1.72 |
| Urea, Week 4, n=280, 277 | 0.04 ± 1.292 | -0.05 ± 1.240 |
| Urea, Week 8, n=212, 278 | 0.04 ± 1.315 | -0.05 ± 1.278 |
| Urea, Week 12, n=270, 276 | -0.01 ± 1.287 | 0.04 ± 1.340 |
| Urea, Week 16, n=255, 269 | 0.02 ± 1.394 | 0.01 ± 1.171 |
| Urea, Week 20, n=260, 272 | -0.07 ± 1.359 | 0.04 ± 1.190 |
| Urea, Week 24, n=261, 268 | 0.09 ± 1.459 | -0.08 ± 1.154 |
| Urea, Week 28, n=253, 268 | 0.02 ± 1.412 | 0.02 ± 1.230 |
| Urea, Week 32, n=255, 268 | 0.16 ± 1.364 | -0.03 ± 1.330 |
| Urea, Week 36, n=254, 261 | 0.05 ± 1.451 | 0.04 ± 1.265 |
| Urea, Week 40, n=250, 266 | 0.07 ± 1.466 | 0.05 ± 1.312 |
| Urea, Week 44, n=258, 263 | 0.12 ± 1.361 | 0.03 ± 1.290 |
| Urea, Week 48, n=247, 262 | 0.09 ± 1.362 | 0.06 ± 2.189 |
Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Units per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=278, 276 | 1.6 ± 23.51 | 1.8 ± 30.92 |
| Week 8, n=211, 278 | 0.8 ± 19.07 | 0.4 ± 27.41 |
| Week 12, n=270, 276 | 1.3 ± 18.55 | 2.5 ± 29.44 |
| Week 16, n=254, 269 | 0.8 ± 20.27 | 1.2 ± 27.24 |
| Week 20, n=260, 270 | 1.6 ± 16.26 | 0.8 ± 27.96 |
| Week 24, n=260, 268 | 0.9 ± 18.74 | 0.9 ± 27.58 |
| Week 28, n=253, 268 | -0.4 ± 16.73 | 1.8 ± 29.09 |
| Week 32, n=254, 268 | 2.9 ± 29.88 | 2.0 ± 34.42 |
| Week 36, n=254, 261 | 1.0 ± 17.45 | -0.1 ± 28.89 |
| Week 40, n=250, 266 | 2.3 ± 22.71 | 0.6 ± 27.95 |
| Week 44, n=258, 263 | 5.7 ± 41.87 | 1.6 ± 29.05 |
| Week 48, n=247, 261 | 0.7 ± 16.14 | 1.1 ± 32.35 |
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| mL/min/1.73/m^2 | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=278, 277 | 6.9 ± 10.16 | -1.2 ± 8.72 |
| Week 8, n=211, 278 | 10.0 ± 11.83 | 0.2 ± 9.13 |
| Week 12, n=270, 276 | 10.7 ± 11.49 | 0.9 ± 9.83 |
| Week 16, n=254, 269 | 10.4 ± 11.28 | -0.3 ± 10.23 |
| Week 20, n=261, 271 | 10.9 ± 11.45 | 0.3 ± 9.90 |
| Week 24, n=261, 268 | 10.5 ± 11.38 | 0.2 ± 9.63 |
| Week 28, n=253, 268 | 10.9 ± 11.90 | 1.0 ± 9.90 |
| Week 32, n=254, 268 | 10.6 ± 11.45 | 1.1 ± 10.05 |
| Week 36, n=254, 262 | 10.3 ± 11.94 | 0.2 ± 10.08 |
| Week 40, n=250, 266 | 10.2 ± 12.57 | 0.7 ± 9.19 |
| Week 44, n=258, 263 | 9.8 ± 11.61 | 1.4 ± 9.88 |
| Week 48, n=247, 261 | 9.5 ± 11.35 | -0.7 ± 10.86 |
Blood samples were collected at Baseline and at Week 48 to assess glucose and fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Only fasting data is presented for glucose and lipids. Baseline value is defined as the last available fasting recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at Week 48 visit (if collected while fasting) minus the Baseline value.
| Millimoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Glucose, Week 48, n=248, 251 | 0.02 ± 1.220 | 0.04 ± 0.923 |
| Total Cholesterol, Week 48, n=240, 239 | 0.09 ± 0.658 | 0.05 ± 0.607 |
| HDL cholesterol, Week 48, n=240, 239 | 0.109 ± 0.2587 | 0.076 ± 0.2478 |
| LDL cholesterol, Week 48, n=238, 237 | 0.122 ± 0.5807 | -0.045 ± 0.5384 |
| Triglycerides, Week 48, n=240, 239 | -0.085 ± 0.7167 | 0.073 ± 0.8361 |
Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Grams per mole | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Urine albumin/creatinine ratio, Week 4,n=199, 194 | 0.36 ± 6.714 | 0.23 ± 4.062 |
| Urine albumin/creatinine ratio, Week 24,n=137, 184 | 0.30 ± 4.941 | 1.06 ± 7.186 |
| Urine albumin/creatinine ratio, Week 48,n=181, 184 | -0.53 ± 17.469 | 0.19 ± 3.944 |
| Urine protein/creatinine, Week 4, n=211, 215 | -0.16 ± 18.641 | 0.19 ± 6.439 |
| Urine protein/creatinine, Week 24, n=151, 204 | 2.23 ± 35.187 | 1.32 ± 12.171 |
| Urine protein/creatinine, Week 48, n=194, 197 | -1.86 ± 21.898 | 0.26 ± 8.180 |
Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Micromoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=277, 272 | -519.5 ± 9558.55 | -429.0 ± 9540.31 |
| Week 24, n=193, 258 | -597.4 ± 9405.95 | -17.1 ± 9575.04 |
| Week 48, n=260, 258 | -1359.2 ± 9059.43 | -505.4 ± 8873.05 |
Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Micromoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=275, 273 | 1.842 ± 18.4414 | -0.693 ± 18.4830 |
| Week 24, n=192, 260 | 0.585 ± 19.2777 | -0.689 ± 16.9500 |
| Week 48, n=259, 258 | 0.043 ± 17.3741 | 0.304 ± 16.7073 |
Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Nanomoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48 | -0.33 ± 0.938 | -0.24 ± 0.932 |
Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.
| Ratio of urine density to water density | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=271, 266 | -0.0004 ± 0.00837 | -0.0005 ± 0.00798 |
| Week 24, n=191, 252 | -0.0001 ± 0.00805 | -0.0002 ± 0.00825 |
| Week 48, n=255, 252 | -0.0009 ± 0.00784 | -0.0007 ± 0.00783 |
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| pH | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4, n=271, 266 | 0.12 ± 0.833 | 0.01 ± 0.884 |
| Week 24, n=191, 252 | -0.01 ± 0.889 | -0.07 ± 0.910 |
| Week 48, n=255, 252 | 0.01 ± 0.926 | -0.10 ± 0.988 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. All Maintenance Phase adverse events (start date occurring on or after the date of first dose of randomized study treatment) leading to withdrawal have been presented.
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48 | 9 | 4 |
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the last available recorded fasting value up to and including the date of first Maintenance Phase dose of IP. Percentage change from baseline is calculated as: value at Week 48 (if collected while fasting) minus Baseline value divided by Baseline value multiplied by 100.
| Millimoles per liter | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Cholesterol, Week 48, Overall, n=240, 239 | 5.09 ± 15.695 | 2.32 ± 14.456 |
| HDL cholesterol, Week 48, Overall, n=240, 239 | 15.448 ± 78.5208 | 7.361 ± 20.3088 |
| LDL cholesterol, Week 48, Overall, n=238, 237 | 7.048 ± 29.2139 | 0.462 ± 23.9648 |
| Triglycerides, Week 48, Overall, n=240, 239 | 2.633 ± 44.1663 | 14.252 ± 62.2823 |
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Phenotypic Resistance data for following drugs :CAB,dolutegravir(DTG),elvitegravir (EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI),atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),ritonavir(RTV), saquinavir(SQV) and tipranavir (TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance (FC\>clinical higher cutoff/biologic cutoff),partially sensitive (FC=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC\<=clinical lower cutoff/biologic cutoff). The CVF population comprised of all participants in ITT-E population who met CVF criteria
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| INI, CAB, sensitive | 0 | 3 |
| INI, CAB, partially sensitive | 0 | 0 |
| INI, CAB, resistant | 3 | 0 |
| INI, DTG, sensitive | 3 | 3 |
| INI, DTG, partially sensitive | 0 | 0 |
| INI, DTG, resistant | 0 | 0 |
| INI, EVG, sensitive | 0 | 3 |
| INI, EVG, partially sensitive | 0 | 0 |
| INI, EVG, resistant | 3 | 0 |
| INI, RAL, sensitive | 0 | 3 |
| INI, RAL, partially sensitive | 0 | 0 |
| INI, RAL, resistant | 3 | 0 |
| NNRTI, DLV, sensitive | 1 | 3 |
| NNRTI, DLV, partially sensitive | 0 | 0 |
| NNRTI, DLV, resistant | 2 | 0 |
| NNRTI, EFV, sensitive | 1 | 3 |
| NNRTI, EFV, partially sensitive | 0 | 0 |
| NNRTI, EFV, resistant | 2 | 0 |
| NNRTI, ETR, sensitive | 2 | 3 |
| NNRTI, ETR, partially sensitive | 1 | 0 |
| NNRTI, ETR, resistant | 0 | 0 |
| NNRTI, NVP, sensitive | 1 | 3 |
| NNRTI, NVP, partially sensitive | 0 | 0 |
| NNRTI, NVP, resistant | 2 | 0 |
| NNRTI, RPV, sensitive | 1 | 3 |
| NNRTI, RPV, partially sensitive | 0 | 0 |
| NNRTI, RPV, resistant | 2 | 0 |
| NRTI, 3TC, sensitive | 3 | 3 |
| NRTI, 3TC, partially sensitive | 0 | 0 |
| NRTI, 3TC, resistant | 0 | 0 |
| NRTI, ABC, sensitive | 3 | 3 |
| NRTI, ABC, partially sensitive | 0 | 0 |
| NRTI, ABC, resistant | 0 | 0 |
| NRTI, FTC, sensitive | 3 | 3 |
| NRTI, FTC, partially sensitive | 0 | 0 |
| NRTI, FTC, resistant | 0 | 0 |
| NRTI, TDF, sensitive | 1 | 3 |
| NRTI, TDF, partially sensitive | 2 | 0 |
| NRTI, TDF, resistant | 0 | 0 |
| NRTI, ZDV, sensitive | 2 | 3 |
| NRTI, ZDV, partially sensitive | 0 | 0 |
| NRTI, ZDV, resistant | 1 | 0 |
| NRTI, d4T, sensitive | 3 | 3 |
| NRTI, d4T, partially sensitive | 0 | 0 |
| NRTI, d4T, resistant | 0 | 0 |
| NRTI, ddI, sensitive | 3 | 3 |
| NRTI, ddI, partially sensitive | 0 | 0 |
| NRTI, ddI, resistant | 0 | 0 |
| PI, ATV, sensitive | 3 | 3 |
| PI, ATV, partially sensitive | 0 | 0 |
| PI, ATV, resistant | 0 | 0 |
| PI, DRV, sensitive | 3 | 3 |
| PI, DRV, partially sensitive | 0 | 0 |
| PI, DRV, resistant | 0 | 0 |
| PI, FPV, sensitive | 3 | 3 |
| PI, FPV, partially sensitive | 0 | 0 |
| PI, FPV, resistant | 0 | 0 |
| PI, IDV, sensitive | 3 | 3 |
| PI, IDV, partially sensitive | 0 | 0 |
| PI, IDV, resistant | 0 | 0 |
| PI, LPV, sensitive | 3 | 3 |
| PI, LPV, partially sensitive | 0 | 0 |
| PI, LPV, resistant | 0 | 0 |
| PI, NFV, sensitive | 3 | 3 |
| PI, NFV, partially sensitive | 0 | 0 |
| PI, NFV, resistant | 0 | 0 |
| PI, RTV, sensitive | 3 | 3 |
| PI, RTV, partially sensitive | 0 | 0 |
| PI, RTV, resistant | 0 | 0 |
| PI, SQV, sensitive | 3 | 3 |
| PI, SQV, partially sensitive | 0 | 0 |
| PI, SQV, resistant | 0 | 0 |
| PI, TPV, sensitive | 3 | 3 |
| PI, TPV, partially sensitive | 0 | 0 |
| PI, TPV, resistant | 0 | 0 |
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
| Participants | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| INI, DTG, resistant | 0 | 0 |
| INI, DTG, resistance possible | 2 | 0 |
| INI, DTG, sensitive | 1 | 3 |
| INI, EVG, resistant | 2 | 0 |
| INI, EVG, resistance possible | 0 | 0 |
| INI, EVG, sensitive | 1 | 3 |
| INI, RAL, resistant | 2 | 0 |
| INI, RAL, resistance possible | 0 | 0 |
| INI, RAL, sensitive | 1 | 3 |
| NNRTI, DLV, resistant | 0 | 0 |
| NNRTI, DLV, resistance possible | 0 | 0 |
| NNRTI, DLV, sensitive | 3 | 3 |
| NNRTI, EFV, resistant | 0 | 0 |
| INI, EFV, resistance possible | 1 | 0 |
| NNRTI, EFV, sensitive | 2 | 3 |
| NNRTI, ETR, resistant | 0 | 0 |
| NNRTI, ETR, resistance possible | 0 | 0 |
| NNRTI, ETR, sensitive | 3 | 3 |
| NNRTI, NVP, resistant | 0 | 0 |
| NNRTI, NVP, resistance possible | 1 | 0 |
| NNRTI, NVP, sensitive | 2 | 3 |
| NNRTI, RPV, resistant | 3 | 0 |
| NNRTI, RPV, resistance possible | 0 | 0 |
| NNRTI, RPV, sensitive | 0 | 3 |
| NRTI, 3TC, resistant | 0 | 0 |
| NNRTI, 3TC, resistance possible | 0 | 0 |
| NRTI, 3TC, sensitive | 3 | 3 |
| NRTI, ABC, resistant | 0 | 0 |
| NRTI, ABC, resistance possible | 0 | 0 |
| NRTI, ABC, sensitive | 3 | 3 |
| NRTI, FTC, resistant | 0 | 0 |
| NRTI, FTC, resistance possible | 0 | 0 |
| NRTI, FTC, sensitive | 3 | 3 |
| NRTI, TDF, resistant | 0 | 0 |
| NRTI, TDF, resistance possible | 0 | 0 |
| NRTI, TDF, sensitive | 3 | 3 |
| NRTI, ZDV, resistant | 0 | 0 |
| NRTI, ZDV, resistance possible | 0 | 0 |
| NRTI, ZDV, sensitive | 3 | 3 |
| NRTI, d4T, resistant | 0 | 0 |
| NRTI, d4T, resistance possible | 0 | 0 |
| NRTI, d4T, sensitive | 3 | 3 |
| NRTI, ddI, resistant | 0 | 0 |
| NRTI, ddI, resistance possible | 0 | 0 |
| NRTI, ddI, sensitive | 3 | 3 |
| PI, ATV, resistant | 0 | 0 |
| PI, ATV, resistance possible | 0 | 0 |
| PI, ATV, sensitive | 3 | 3 |
| PI, ATV/r, resistant | 0 | 0 |
| PI, ATV/r, resistance possible | 0 | 0 |
| PI, ATV/r, sensitive | 3 | 3 |
| PI, DRV/r, resistant | 0 | 0 |
| PI, DRV/r, resistance possible | 0 | 0 |
| PI, DRV/r, sensitive | 3 | 3 |
| PI, FPV/r, resistant | 0 | 0 |
| PI, FPV/r, resistance possible | 0 | 0 |
| PI, FPV/r, sensitive | 3 | 3 |
| PI, IDV/r, resistant | 0 | 0 |
| PI, IDV/r, resistance possible | 0 | 0 |
| PI, IDV/r, sensitive | 3 | 3 |
| PI, LPV/r, resistant | 0 | 0 |
| PI, LPV/r, resistance possible | 0 | 0 |
| PI, LPV/r, sensitive | 3 | 3 |
| PI, NFV, resistant | 0 | 0 |
| PI, NFV, resistance possible | 0 | 0 |
| PI, NFV, sensitive | 3 | 3 |
| PI, RTV, resistant | 0 | 0 |
| PI, RTV, resistance possible | 0 | 0 |
| PI, RTV, sensitive | 3 | 3 |
| PI, SQV/r, resistant | 0 | 0 |
| PI, SQV/r, resistance possible | 0 | 0 |
| PI, SQV/r, sensitive | 3 | 3 |
| PI, TPV/r, resistant | 0 | 0 |
| PI, TPV/r, resistance possible | 1 | 0 |
| PI, TPV/r, sensitive | 2 | 3 |
AUC values are Bayesian pharmacokinetic (PK) parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for CAB LA. The PK Population includes all participants who received CAB and / or RPV and undergo PK sampling during the study, and provide CAB and /or RPV plasma concentration data.
| Hours*micrograms per milliliter | CAB LA |
|---|---|
| Area Under the Curve (AUC) for CAB LA | 2517.40 (2439.876 to 2597.394) |
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for RPV LA
| Hours*nanograms per milliliter | CAB LA |
|---|---|
| AUC for RPV LA | 63989.13 (61489.692 to 66590.156) |
Blood samples were collected at indicated time points for PK analysis of CAB LA.
| Microgram per milliliter | CAB LA |
|---|---|
| Pre-dose, Week 8, n=250 | 1.5616 (1.4508 to 1.6808) |
| Pre-dose, Week 12, n=237 | 2.0141 (1.8990 to 2.1362) |
| Pre-dose, Week 16, n=215 | 2.0960 (1.9740 to 2.2255) |
| Pre-dose, Week 20, n=233 | 2.1739 (2.0580 to 2.2963) |
| Pre-dose, Week 24, n=227 | 2.3827 (2.2731 to 2.4976) |
| Pre-dose, Week 28, n=220 | 2.4683 (2.3421 to 2.6013) |
| Pre-dose, Week 32, n=219 | 2.6729 (2.5339 to 2.8196) |
| Pre-dose, Week 36, n=215 | 2.8590 (2.7096 to 3.0165) |
| Pre-dose, Week 40, n=210 | 2.9378 (2.7872 to 3.0966) |
| Pre-dose, Week 44, n=217 | 3.0133 (2.8739 to 3.1595) |
| Pre-dose, Week 48, n=197 | 3.1325 (2.9454 to 3.3315) |
Blood samples were collected at indicated time points for PK analysis of RPV LA.
| Nanograms per milliliter | RPV LA |
|---|---|
| Pre-dose, Week 8, n=251 | 41.23 (38.74 to 43.88) |
| Pre-dose, Week 12, n=236 | 46.86 (43.82 to 50.12) |
| Pre-dose, Week 16, n=217 | 50.01 (47.06 to 53.15) |
| Pre-dose, Week 20, n=233 | 52.76 (49.79 to 55.91) |
| Pre-dose, Week 24, n=228 | 55.56 (52.48 to 58.82) |
| Pre-dose, Week 28, n=220 | 59.46 (55.43 to 63.79) |
| Pre-dose, Week 32, n=220 | 66.88 (62.95 to 71.05) |
| Pre-dose, Week 36, n=215 | 69.09 (64.90 to 73.55) |
| Pre-dose, Week 40, n=210 | 75.71 (71.38 to 80.29) |
| Pre-dose, Week 44, n=216 | 77.96 (73.87 to 82.28) |
| Pre-dose, Week 48, n=197 | 82.38 (77.82 to 87.22) |
Blood samples will be collected at indicated time points for PK analysis of CAB LA.
| Micrograms per milliliter | CAB LA |
|---|---|
| Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41 | 4.0334 (3.8488 to 4.2269) |
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
| Nanograms per milliliter | RPV LA |
|---|---|
| Cmax in Plasma for RPV LA Evaluable at Week 41 | 106.3 (101.03 to 111.28) |
Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.
No measurements were reported for this outcome.
PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis
| Scores on a scale | CAB LA + RPV LA (Q4W) |
|---|---|
| Bother of ISRs, Week 41 | -0.14 ± 0.551 |
| Bother of ISRs, Week 48 | -0.14 ± 0.639 |
| Leg movement, Week 41 | -0.58 ± 0.880 |
| Leg movement, Week 48 | -0.63 ± 0.964 |
| Sleep, Week 41 | -0.57 ± 0.925 |
| Sleep, Week 48 | -0.58 ± 1.033 |
| Acceptance, Week 41 | -0.36 ± 0.959 |
| Acceptance, Week 48 | -0.40 ± 0.943 |
PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment, following visit and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis.
| Percentage of participants | CAB LA + RPV LA (Q4W) |
|---|---|
| Local reactions, Week 5, totally acceptable, n=270 | 47 |
| Local reactions,Week 5, very acceptable, n=270 | 29 |
| Local reactions, Week 5, moderate, n=270 | 16 |
| Local reactions, Week 5, little acceptable, n=270 | 6 |
| Local reactions, Week 5, not at all, n=270 | 3 |
| Pain, Week 5, totally acceptable, n=270 | 33 |
| Pain, Week 5, very acceptable, n=270 | 28 |
| Pain, Week 5, moderate acceptable, n=270 | 24 |
| Pain, Week 5, little acceptable, n=270 | 11 |
| Pain, Week 5, not at all acceptable, n=270 | 5 |
| Local reactions, week 41, totally, n=276 | 57 |
| Local reactions, Week 41, very acceptable, n=276 | 29 |
| Local reactions, Week 41, moderate, n=276 | 11 |
| Local reactions, Week 41, little acceptable, n=276 | 3 |
| Local reactions, Week 41, not at all, n=276 | 1 |
| Pain, Week 41, totally acceptable, n=276 | 45 |
| Pain, Week 41, very acceptable, n=276 | 35 |
| Pain, Week 41, moderate acceptable, n=276 | 14 |
| Pain, Week 41, little acceptable, n=276 | 4 |
| Pain, Week 41, not at all acceptable, n=276 | 1 |
| Local reactions, week 48, totally, n=278 | 55 |
| Local reactions, Week 48, very acceptable, n=278 | 31 |
| Local reactions, Week 48, moderate, n=278 | 11 |
| Local reactions, Week 48, little acceptable, n=278 | 2 |
| Local reactions, Week 48, not at all, n=278 | 1 |
| Pain, Week 48, totally acceptable, n=278 | 49 |
| Pain, Week 48, very acceptable, n=278 | 35 |
| Pain, Week 48, moderate acceptable, n=278 | 12 |
| Pain, Week 48 little acceptable, n=278 | 3 |
| Pain, Week 48, not at all acceptable, n=278 | 1 |
The HATQoL questionnaire was used to assess health related QoL (HRQoL). It comprises of three dimensions: life satisfaction (LISAT), medication worries (MEDWO) and disclosure worries (DISWO). For LISAT domain, each question is scored as 1-5, where 5 corresponds to satisfaction 'all of time' and 1 as 'none of time'. Total score for the LISAT domain (sum of item scores for questions 1a to 1d) is transformed to a 0-100 scale using formula:\[100 divided by (20 minus 4)\]\*(raw total score for LISAT minus 4). Higher the LISAT score, greater satisfaction to life. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 24, n=252, 253 | 0.4 (-1.3 to 2.1) | -0.8 (-2.5 to 0.9) |
| Week 48, n=253, 258 | 0.9 (-0.8 to 2.6) | 0.0 (-1.6 to 1.7) |
The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the MEDWO domain, each question is scored as 1-5, where 5 is associated with medication worry 'none of the time' and 1 as 'all of the time'. The total score for the MEDWO domain (sum of item scores for questions 2a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for MEDWO minus 5). Higher MEDWO scores correspond to lower medication worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 24, n=252, 253 | 3.2 (1.6 to 4.7) | 1.4 (-0.1 to 3.0) |
| Week 48, n=253, 258 | 1.4 (-0.3 to 3.1) | 1.3 (-0.4 to 3.0) |
The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the DISWO domain, each question is scored as 1-5, where 5 is associated with disclosure worry 'none of the time' and 1 as 'all of the time'. The total score for the DISWO domain (sum of item scores for questions 3a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for DISWO minus 5). Higher DISWO total scores correspond to lower disclosure worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 24, n=252, 253 | -0.8 (-3.9 to 2.3) | 0.5 (-2.6 to 3.6) |
| Week 48, n=253, 258 | -3.6 (-6.6 to -0.6) | 1.1 (-1.9 to 4.0) |
The SF-12 questionnaire consists of 7 questions which measures degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. HRQoL using SF-12 for physical component summary (PCS) and mental component summary (MCS) were assessed for two treatment groups.Missing component scores was imputed using LOCF.PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com).The higher the score, the better will be the health status.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| MCS, Week 24, n=251, 253 | -0.045 (-0.963 to 0.874) | -1.066 (-1.980 to -0.151) |
| MCS, Week 48, n=252, 258 | -0.013 (-0.973 to 0.947) | -1.116 (-2.065 to -0.167) |
| PCS, Week 24, n=251, 253 | -0.019 (-0.568 to 0.531) | -0.201 (-0.748 to 0.347) |
| PCS, Week 48, n=252, 258 | -0.294 (-0.881 to 0.293) | -0.126 (-0.706 to 0.455) |
HIVTSQs (status version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value. Adjusted mean and 95% CI of adjusted mean values has been presented.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 4b, n=257, 0 | 0.2 (-0.5 to 1.0) | — |
| Week 24, n=257, 253 | 1.6 (0.8 to 2.5) | -0.5 (-1.4 to 0.3) |
| Week 44, n=257, 256 | 1.3 (0.5 to 2.1) | 0.5 (-0.3 to 1.4) |
HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores representedeterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Change in Treatment Satisfaction Over Time Using HIVTSQc at Week 48 | 29.6 ± 0.49 | 25.5 ± 0.48 |
HIVTSQs (status version) is a 12 item questionnaire. The individual item scores are ratedas 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. LOCF was used as primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Item 1; Week 4b, n=257, 0 | -0.0 ± 0.91 | — |
| Item 1; Week 24, n=257, 255 | 0.1 ± 0.96 | -0.0 ± 0.95 |
| Item 1; Week 44, n=257, 258 | 0.0 ± 1.02 | 0.0 ± 0.93 |
| Item 2; Week 4b, n=257, 0 | 0.0 ± 0.61 | — |
| Item 2; Week 24, n=257, 255 | -0.0 ± 0.62 | -0.0 ± 0.87 |
| Item 2; Week 44, n=257, 258 | -0.1 ± 0.61 | 0.1 ± 0.62 |
| Item 3; Week 4b, n=257, 0 | 0.2 ± 1.02 | — |
| Item 3; Week 24, n=257, 255 | -0.1 ± 1.21 | -0.0 ± 1.16 |
| Item 3; Week 44, n=257, 258 | -0.0 ± 1.35 | 0.1 ± 1.22 |
| Item 4; Week 4b, n=257, 0 | 0.1 ± 1.02 | — |
| Item 4; Week 24, n=257, 255 | 0.1 ± 1.03 | -0.0 ± 1.14 |
| Item 4; Week 44, n=257, 258 | 0.0 ± 1.08 | 0.1 ± 1.10 |
| Item 5; Week 4b, n=257, 0 | 0.1 ± 0.98 | — |
| Item 5; Week 24, n=257, 255 | 0.4 ± 1.22 | -0.1 ± 1.05 |
| Item 5; Week 44, n=257, 258 | 0.3 ± 1.28 | 0.0 ± 1.06 |
| Item 6; Week 4b, n=257, 0 | 0.1 ± 1.40 | — |
| Item 6; Week 24, n=257, 255 | 0.3 ± 1.47 | -0.1 ± 1.63 |
| Item 6; Week 44, n=257, 258 | 0.3 ± 1.70 | 0.2 ± 1.48 |
| Item 7; Week 4b, n=257, 0 | 0.0 ± 0.83 | — |
| Item 7; Week 24, n=257, 255 | 0.0 ± 0.79 | 0.0 ± 1.02 |
| Item 7; Week 44, n=257, 258 | 0.1 ± 0.85 | 0.1 ± 0.95 |
| Item 8; Week 4b, n=257, 0 | -0.0 ± 1.06 | — |
| Item 8; Week 24, n=257, 255 | 0.2 ± 1.22 | -0.0 ± 1.11 |
| Item 8; Week 44, n=257, 258 | 0.2 ± 1.27 | 0.1 ± 1.16 |
| Item 9; Week 4b, n=257, 0 | -0.1 ± 0.85 | — |
| Item 9; Week 24, n=257, 255 | 0.0 ± 0.78 | -0.1 ± 1.11 |
| Item 9; Week 44, n=257, 258 | 0.0 ± 0.85 | 0.0 ± 1.01 |
| Item 10; Week 4b, n=257, 0 | -0.1 ± 1.16 | — |
| Item 10; Week 24, n=257, 256 | 0.4 ± 1.28 | -0.1 ± 1.35 |
| Item 10; Week 44, n=257, 259 | 0.4 ± 1.33 | -0.0 ± 1.20 |
| Item 11; Week 4b, n=257, 0 | -0.0 ± 1.02 | — |
| Item 11; Week 24, n=257, 255 | 0.2 ± 1.18 | -0.1 ± 0.99 |
| Item 11; Week 44, n=257, 258 | 0.1 ± 1.18 | 0.0 ± 0.97 |
| Item 12; Week 4b, n=257, 0 | -0.0 ± 0.99 | — |
| Item 12; Week 24, n=257, 255 | -0.4 ± 1.26 | 0.1 ± 1.19 |
| Item 12; Week 44, n=257, 258 | -0.5 ± 1.20 | 0.1 ± 1.29 |
ACCEPT questionnaire is generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication. It consists 25 items, capturing six dimensions. 3 questions focusing on general acceptance of study medication were analyzed. Items scores are rated as 1-5 :1-totally disagree,2-somewhat disagree,3-somewhat agree,4-totally agree and 5-I don't know. The acceptance domain score (ranging from 0 to 100) is calculated using the following formula:100\*(mean of recoded items in dimension minus 1) divided by 2.LOCF was primary method of analysis. Measure type is mean for adjusted mean and dispersion measure: 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
| Scores on a scale | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Week 8, n=253, 256 | 3.3 (0.8 to 5.8) | 1.2 (-1.3 to 3.6) |
| Week 24, 255, 261 | 3.7 (1.1 to 6.4) | 1.1 (-1.5 to 3.7) |
| Week 48, n=255, 262 | 3.0 (0.4 to 5.6) | 0.8 (-1.7 to 3.4) |
The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.
| Scores on a scale | CAB LA + RPV LA (Q4W) |
|---|---|
| Week 5 | 1.8 ± 2.78 |
| Week 40 | 0.8 ± 2.72 |
| Week 41 | 0.4 ± 2.69 |
Collected over Non-serious AEs and SAEs were collected up to an average of 59 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | 0/283 (0%) | 18/283 (6.4%) | 252/283 (89%) |
| ABC/ DTG/ 3TC | 0/283 (0%) | 12/283 (4.2%) | 138/283 (48.8%) |
| Event | CAB LA+RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Hepatitis AInfections and infestations | 3/283 | 1/283 |
| Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/283 | 1/283 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/283 | 0/283 |
| Anal abscessInfections and infestations | 0/283 | 1/283 |
| Anal fistulaGastrointestinal disorders | 1/283 | 0/283 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/283 | 0/283 |
| Bile duct stoneHepatobiliary disorders | 1/283 | 0/283 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/283 | 1/283 |
| Bronchitis pneumococcalInfections and infestations | 0/283 | 1/283 |
| CholecystitisHepatobiliary disorders | 1/283 | 0/283 |
| Event | CAB LA+RPV LA (Q4W) | ABC/ DTG/ 3TC |
|---|---|---|
| Injection site painGeneral disorders | 227/283 | 0/283 |
| NasopharyngitisInfections and infestations | 56/283 | 48/283 |
| Injection site noduleGeneral disorders | 44/283 | 0/283 |
| HeadacheNervous system disorders | 39/283 | 21/283 |
| Upper respiratory tract infectionInfections and infestations | 38/283 | 28/283 |
| Injection site indurationGeneral disorders | 38/283 | 0/283 |
| DiarrhoeaGastrointestinal disorders | 32/283 | 25/283 |
| InfluenzaInfections and infestations | 25/283 | 20/283 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 23/283 | 13/283 |
| Injection site swellingGeneral disorders | 23/283 | 0/283 |
| Age, Continuous(Years) | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC | Total |
|---|---|---|---|
| Mean | 35.9 ± 10.17 | 36.0 ± 9.82 | 35.9 ± 9.99 |
| Sex: Female, Male(Participants) | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC | Total |
|---|---|---|---|
| Female | 63 | 64 | 127 |
| Male | 220 | 219 | 439 |
| Race/Ethnicity, Customized(Participants) | CAB LA + RPV LA (Q4W) | ABC/ DTG/ 3TC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 6 | 9 |
| Asian-Central/South Asian Heritage | 2 | 1 | 3 |
| Asian-East Asian Heritage | 1 | 2 | 3 |
| Asian-South East Asian Heritage | 1 | 0 | 1 |
| Asian-Japanese Heritage | 8 | 12 | 20 |
| Black or African American | 47 | 56 | 103 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| White-Arabic/North African Heritage | 5 | 3 | 8 |
| White-White /Caucasian/European Heritage | 211 | 198 | 409 |
| Multiple | 4 | 3 | 7 |
| Missing | 0 | 2 | 2 |
Showing the first 100 of 108 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Oct 2016 to primary completion in Aug 2018, 22 months.
Results were first posted in Oct 2019, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 22 months is close to that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir